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Abstract 
 
Uveal melanoma is a rare disease causing significant mortality. Metastatic disease - 
for which there is no treatment - often occurs before the primary tumour is 
diagnosed. In addition to enucleation, there are many globe-sparing ways of treating 
the primary tumour. Fractionated stereotactic radiotherapy is one such treatment, 
delivering a homogenous dose of radiation to the tumour and allowing normal tissue 
the chance to recover between fractions. 
 
The aim of this thesis was to evaluate the effectiveness of fractionated stereotactic 
radiotherapy for the treatment of uveal melanoma in the New Zealand population. 
The main outcome measurements were local tumour control, visual acuity, 
radiogenic side effects and metastatic death. 
 
A retrospective audit of clinical notes was performed on all patients with uveal 
melanoma treated with fractionated stereotactic radiotherapy in Dunedin, New 
Zealand, from July 2001 to December 2007. All twenty-seven patients treated during 
this period were included. 
 
Local control was achieved in all patients. Three patients required secondary 
enucleation for intractable pain, recurrent vitreous cavity haemorrhage, and 
recurrent retinal detachment. Visual acuity deteriorated in eighteen of the remaining 
twenty-four patients (75%), and mean Snellen acuity dropped from 6/6 at baseline to 
6/21 at final follow-up. Eight patients developed radiation retinopathy, one patient 
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developed optic neuropathy, and two patients developed neovascular glaucoma. At 
final follow-up, three patients were known to have died of metastatic disease. 
 
Fractionated stereotactic radiotherapy is an eye-sparing treatment option for patients 
with uveal melanoma. Data from this study supports international literature that this 
is a useful addition to the treatment armamentarium for this cancer. 
 
 





I would like to thank my supervisors Dr Lyndell Kelly and Professor ACB Molteno. I 
acknowledge the OSNZ Postgraduate Education Trust Fund for their financial 
support. I thank my family and friends for their unfailing encouragement, especially 
Thérèse Oliver for her patience and technical support, and Anne-Marie Yardley. 
 
To Mrs Tui Bevin, research fellow, proof-reader and voice of reason: thank you, 
thank you, thank you. 
 
   v 
Table of Contents 
Abstract .................................................................................................................................... ii	  
Acknowledgements .............................................................................................................. iv	  
List of Tables ........................................................................................................................ vii	  
List of Figures ..................................................................................................................... viii	  
List of Abbreviations ........................................................................................................... ix	  
Introduction ............................................................................................................................. 1	  
1.1	   Background ............................................................................................................................... 1	  
1.2	   Aim ............................................................................................................................................. 1	  
1.3	   Chapter outlines ....................................................................................................................... 2	  
1.4	   Nomenclature ........................................................................................................................... 2	  
Pathophysiology ..................................................................................................................... 3	  
2.1	   Anatomy of the uveal tract ..................................................................................................... 3	  
2.2	   Tumour biology ....................................................................................................................... 5	  
2.3	   Cytogenetics .............................................................................................................................. 6	  
2.4	   Tumour classification ........................................................................................................... 10	  
2.5	   Metastasis ................................................................................................................................ 13	  
2.6	   Vascular endothelial growth factor .................................................................................... 15	  
Clinical features .................................................................................................................... 20	  
3.1	    Epidemiology ......................................................................................................................... 20	  
3.2	    Phenotypic associations ....................................................................................................... 21	  
3.3	    Clinical presentation ............................................................................................................ 22	  
3.4	    Naevi and small tumours .................................................................................................... 25	  
3.5	    Ancillary testing .................................................................................................................... 27	  
3.6	    Systemic evaluation .............................................................................................................. 30	  
3.7	    Treatment options ................................................................................................................. 30	  
3.8	    Prognosis ................................................................................................................................ 31	  
3.9	    Surveillance of metastatic disease ..................................................................................... 33	  
3.10	   Treatment of metastatic disease ........................................................................................ 36	  
Surgical management ........................................................................................................... 39	  
4.1	    Enucleation ............................................................................................................................. 39	  
4.2	    Tumour biopsy ...................................................................................................................... 41	  
4.3	    Trans-scleral resection ......................................................................................................... 42	  
4.4	    Endoresection ........................................................................................................................ 44	  
 
   vi 
Radiotherapy ......................................................................................................................... 46	  
5.1	    Radiation ................................................................................................................................ 46	  
5.2	    Radiotherapy ......................................................................................................................... 46	  
5.3	    Biologic basis of radiation therapy ................................................................................... 48	  
5.4	    Plaque brachytherapy for uveal melanoma ..................................................................... 52	  
5.5	    Collaborative Ocular Melanoma Study (COMS) ........................................................... 54	  
5.6	    Proton therapy ....................................................................................................................... 56	  
5.7	    Helium ion therapy .............................................................................................................. 57	  
5.8	    Stereotactic radiosurgery and radiotherapy .................................................................... 58	  
5.9	    Side effects of radiotherapy ................................................................................................ 60	  
5.10	   Transpupillary thermal therapy ........................................................................................ 62	  
Aim and Methods ................................................................................................................. 65	  
6.1	    Study design .......................................................................................................................... 65	  
6.2	    Ethics approval ...................................................................................................................... 66	  
6.3	    Pre-treatment investigation and treatment planning .................................................... 66	  
6.4	    Data management and analysis ......................................................................................... 69	  
6.5	    Outcome measures ................................................................................................................ 70	  
Results ..................................................................................................................................... 71	  
7.1	    Baseline characteristics ........................................................................................................ 71	  
7.2	    Local control and eye retention .......................................................................................... 73	  
7.3	    Visual acuity .......................................................................................................................... 74	  
7.4	    Radiation-related side effects ............................................................................................. 75	  
7.5	    Metastatic death .................................................................................................................... 76	  
7.6	    Case report .............................................................................................................................. 76	  
Discussion .............................................................................................................................. 79	  
8.1	    International data .................................................................................................................. 79	  
8.2	    Radiation dose ....................................................................................................................... 83	  
8.3	    Eye retention .......................................................................................................................... 86	  
8.4	    Visual acuity .......................................................................................................................... 83	  
8.5	    Study strengths ...................................................................................................................... 86	  
8.6	    Study limitations .................................................................................................................. 86	  
8.7	    Case study .............................................................................................................................. 87	  
8.8	    Conclusions ............................................................................................................................ 87	  
8.9	    Future directions ................................................................................................................... 88	  
References .............................................................................................................................. 89	  
Appendix 1: Data collection sheet ................................................................................... 114 
Appendix 2: Ethics Approval forms   ----------------------------------------------------------115 
 
   vii 





Table 2.1 COMS tumour size        11 
Table 2.2 TNM classification.       12 
Table 3.1 Criteria for assessing a screening programme    35 
Table 5.1 Isotopes used in plaque brachytherapy of the eye   53 
Table 6.1 Visual acuity conversion       70 
Table 7.1 Patient treatment data       73 
Table 8.1 International SRT series       83 















   viii 




Figure 2.1 Anatomy of the eye       4 
Figure 2.2 TNM tumour size         12 
Figure 2.2 Kaplan–Meier survival curve                            13 
Figure 3.1 Large peripapillary choroidal melanoma                                  23 
Figure 3..2 Large posterior pole choroidal melanoma             23 
Figure 3.3 Peripheral choroidal naevus with overlying drusen  25 
Figure 3.4 Choroidal melanoma      26 
Figure 3.5 Peripheral small choroidal melanoma    26 
Figure 3.6 Normal retinal anatomy on SD-OCT    28 
Figure 3.7 Photos and SD-OCT of choroidal melanoma   28 
Figure 5.1 The cell cycle       50 
Figure 6.1 Gill-Thomas-Cosman Frame     67 
Figure 6.2 Eye monitoring system      68 
Figure 6.3 Planning CT scan       68 





   ix 




ALT  Alanine transaminase 
ARMD Age-related macular degeneration 
AST  Aspartate aminotransferase 
BAP1  BRCA1-associated protein 1 tumour suppressor gene  
BRCA1 Breast cancer 1 gene  
BRVO Branch retinal vein occlusion 
COMS  Collaborative Ocular Melanoma Study 
DNA  Deoxyribonucleic acid 
FDA  Food and Drug Administration 
FDG  Fluorodeoxyglucose 
FFA  Fundus fluorescein angiography 
FNAB  Fine-needle aspiration biopsy 
GGT  Gamma-glutamyl transpeptidase 
GTC  Gill-Thomas-Cosman 
Gy  Gray 
HIF-1! Hypoxia-inducible factor 1 alpha 
LDH  Lactate dehydrogenase 
logMAR Logarithm of the minimum angle of resolution 
MeV  Mega-electronvolt 
MRI  Magnetic resonance imaging 
NF-1  Neurofibromatosis type one 
 
   x 
PET  Positron emission tomography 
RNA  Ribonucleic acid 
SD-OCT Spectral domain-optical coherence tomography 
SRS  Stereotactic radiosurgery 
SRT  Stereotactic radiotherapy 
TNM  Tumour, Node, Metastasis cancer staging 
TTT  Transpupillary thermal therapy 
VEGF  Vascular endothelial growth factor 
VEGF-A Vascular endothelial growth factor subtype A 
VEGFR Vascular endothelial growth factor receptor  
 
 







Uveal melanoma is a rare disease causing considerable morbidity and mortality. 
While research over the last fifty years has led to significant improvements in life 
expectancy for cutaneous melanoma, there has been very little improvement in the 
prognosis of uveal melanoma. As long as local control is achieved, there is no 
evidence to suggest superiority of any particular treatment of the primary uveal 
tumour. Success in treating metastatic disease is disappointing, and given the low 
incidence of this cancer, it is difficult to conduct randomized controlled trials and 
provide a strong evidence base to guide treatment management. 
 
1.2 Aim 
The aim of this thesis was to review the pathophysiology and management of uveal 
melanoma and detail in particular the first cohort of patients with uveal melanoma 
who underwent stereotactic radiotherapy in Dunedin, New Zealand, from July 2001 
to December 2007. There have been a number of case series around the world with 
small data sets and this study will contribute to the current body of knowledge. 
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1.3 Chapter outlines 
The second chapter will describe the pathophysiology and cytogenetics of uveal 
melanoma. Chapter three will present the clinical features and associations of uveal 
melanoma. The following chapter will outline surgical treatment options. Chapter 
five will detail the principles of radiotherapy and its application in the treatment of 
uveal melanoma. Results, methods and discussion are presented in the six, seventh 
and final chapters. 
 
1.4 Nomenclature 
For the purposes of this thesis, the term uveal melanoma refers to ciliary body and 
choroidal melanoma. Iris melanoma is considered to be a different entity with 
different pathophysiology and prognosis.  
 






2.1 Anatomy of the uveal tract 
The uveal tract is the middle vascular layer of the eye, and consists of the iris, ciliary 
body and choroid (see Figure 2.1). It is dark brown in colour and its name is derived 
from its resemblance to a grape (Latin, uva) when exposed after removal of the sclera. 
The uveal tract is derived embryologically from vascular channels, neural crest cells 
and neuroectoderm.2 The iris is located anterior to the crystalline lens, forming the 
boundary between the anterior and posterior chambers of the eye, and controls the 
amount of light transmitted through the pupil, its circular aperture. The number and 
size of melanin pigment granules present in the anterior stromal melanocytes 
determine iris colour. The posterior portion of the iris is lined with a double-layered 
pigment epithelium arranged in an apex-to-apex configuration. 
 
The ciliary body extends from the iris root posteriorly to become continuous with the 
choroid at the ora serrata. The inner portion of the ciliary body is lined with a double 
layer of epithelial cells, the outer layer being pigmented.  These cells are involved in 
the production of aqueous humour. Ciliary processes extend inwards to join the 
zonules, attached to the crystalline lens. The ciliary muscle contracts during 
accommodation, a process that increases the dioptric power of the lens. The choroid 
is the pigmented vascular tissue forming the middle layer of the posterior part of the 
eye. It lies between Bruch’s membrane – external to the retinal pigment epithelium - 
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and the sclera, extending from the ora serrata anteriorly to the optic nerve 
posteriorly. Its main function is to provide oxygen to the outer avascular retina. 
 
 
Figure 2. 1: Anatomy of the eye. From Netter's Clinical Anatomy3  
 
Melanocytes are melanin-producing cells of neural crest origin. They are present in 
the skin, eyes, inner ear, and meninges, and their function in humans includes 
photoprotection, trapping reactive oxygen species, sequestering metal ions, and 
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binding certain drugs and organic chemicals.4 Melanin is a biopolymer stored in 
specialized vesicles called melanosomes. Human melanocytes synthesize two distinct 
types of melanin, both of which are present in uveal melanocytes.5 Melanogenesis 
was thought to only occur during fetal development but evidence is emerging in 
support of the hypothesis that melanogenesis does occur in the adult eye. This has 
been demonstrated by the hyperpigmentary side effects with use of prostaglandin 
analogues in the treatment of glaucoma.4, 5  
 
2.2 Tumour biology  
A neoplasm is an unregulated proliferation of cells. Neoplasia arises from non-lethal 
genetic damage causing clonal expansion of a single progenitor cell. Malignant 
neoplasms invade contiguous tissues and metastasize to distant sites. A melanoma is 
a malignant proliferation of melanocytes. Choroidal melanoma is the most common 
type of uveal melanoma (90%), followed by ciliary body (7%) and iris melanoma 
(3%).6  
 
Angiogenesis, or new vessel formation, is a requirement for the continued growth of 
primary and metastatic cancers. For a tumour to increase in size above a few 
thousand cells (about 1-2 mm3) it needs a new vascular supply.7, 8 Uveal melanoma is 
a highly vascular tumour, and high microvascular density correlates with worse 
survival.9 Tumour angiogenesis is a complex process involving the degradation of 
extracellular matrix, migration and proliferation of post-capillary venule endothelial 
cells and tube formation.10 Many tumours secrete polypeptides and platelet-derived 
growth factors that initiate and regulate the process of angiogenesis. Multiple factors 
exist that can stimulate an angiogenic response, and targets include endothelial cells 
and inflammatory cells to promote vessel formation. The most important angiogenic 
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factors are thought to be VEGF (vascular endothelial growth factor) and basic 
fibroblast growth factor.11 Other factors play an important role, including angiogenic 
inhibitors, adhesion molecules, matrix metalloproteinases and plasmin. 
 
2.3 Cytogenetics 
Carcinogenesis, or cancer formation, is a multistep process at phenotypic and genetic 
levels resulting from the accumulation of mutations. Six essential alterations in cell 
physiology, universal to all cancers, collectively dictate malignant growth:12 self-
sufficiency in growth signals; insensitivity to growth inhibition signals; evasion of 
apoptosis; limitless replicative potential; sustained angiogenesis; and tissue invasion 
and metastasis. This transformation is a multi-stage process that occurs over a period 
of years. It is estimated that a minimum of four mutated genes are required for the 
transformation of a normal cell into a malignant phenotype.11 Several groups have 
demonstrated that these ‘hallmarks of cancer’ can be applied to uveal melanoma 
pathogenesis, and that genetic and epigenetic events in the development and 
dissemination of uveal melanoma enable malignant uveal melanocytes to proliferate 
and survive autonomously.13 
 
Cancer may be caused by a chance mutation, or chemical substances, infectious 
agents, radiation or inherited genes. These cause mutations in genes that regulate cell 
growth, death and repair. The unregulated growth of cancer cells results from the 
sequential acquisition of somatic mutations in four kinds of normal regulatory genes:  
 
1. Proto-oncogenes are normal genes that promote cell growth and are ubiquitous 
in normal cells. These genes become oncogenes as a result of mutation, driving 
the malignant transformation of normal cells into cancerous cells and promoting 
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uninhibited cellular proliferation. Mutation of a single allele leads to gain-of-
function and cellular transformation; thus they are referred to as dominant 
mutations.  
2. The mutation of genes involved in apoptosis causes cell division even in the 
presence of DNA damage.  
3. DNA mismatch repair genes normally maintain the integrity of the genome and 
DNA replication, with inactivation allowing the successive accumulation of 
further mutations.  
4. Tumour suppressor genes are also present in normal cells. Their function is to 
inhibit cellular proliferation. Mutation causes loss-of-function and the inhibitory 
activities of tumour suppressor genes are inactivated, permitting unregulated cell 
growth. 
 
Epigenetics refers to the molecular mechanisms resulting in reversible and heritable 
changes in gene expression beyond those caused by alterations in DNA sequence. 
These mechanisms ultimately determine which genes are expressed and which are 
kept silent, and largely account for phenotypic variation between individuals with 
identical genotypes. Principal epigenetic mechanisms include DNA methylation, 
histone modification, and non-coding RNA regulation.14 These mechanisms are also 
likely to contribute to the development and function of self-renewing ‘cancer stem 
cells’.  
 
Since the early 1980s, karyotype analyses of uveal melanoma have found an 
association with alterations of chromosomes 3, 6 and 8,15-18 linking them to metastatic 
death.19-22 Common genetic changes are loss of 3p and 6q and gain of 6p and 8q.23-25 
The most common karyotypic abnormality in uveal melanoma is monosomy 3, with 
the loss of an entire chromosome. The consistent loss of such a large chromosome has 
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never been reported for any other tumour type.26 The frequent loss of a specific 
chromosome is thought to represent one step in the inactivation of a tumour 
suppressor gene residing on the lost chromosome.27 Inactivation of the second gene 
could result from a deletion, point mutation or the inhibition of its expression due to 
epigenetic mechanisms.  
 
Monosomy 3 is associated with aggressive tumour behaviour. Prescher et al in 1996 
reported a three-year relapse-free survival rate of 50% in patients with monosomy 3, 
compared to 100% in patients whose tumours retained both chromosomes.20 They 
also found that metastasis in the absence of monosomy 3 is extremely rare, which has 
been confirmed by others.19, 20, 28 Scholes found that monosomy 3 also correlates with 
a poor prognosis after treatment, noting its greater association with metastatic 
disease than the presence of other tumour features such as epithelioid histology, 
PAS+ loops, ciliary body involvement, or large basal tumour diameter.28 The high 
frequency of monosomy 3 may indicate that there is a suppressor locus for uveal 
melanoma on this chromosome. However, simple determination of monosomy 3 is 
challenging as the chromosomal defect can be masked by (1) a cryptic or partial 
deletion;29 (2) acquired homozygosity (isodisomy) with duplication of chromosome 3 
from the same parent chromosome, or (3) modulation by other chromosomal errors, 
such as 6p or 8q gain.30 
 
Other frequently observed abnormalities involve chromosomes 6 and 8. 
Abnormalities in chromosomes 3 and 8 tend to occur together, with multiplication of 
8q,26, 31, 32 and have a poor outcome.21 Chromosome 8 abnormalities are associated 
with large tumour size and aggressive histology.25 Trisomy 8, duplication of 8q or 
isochromosome 8 occurs frequently and has been found in 50-60% of enucleated 
tumours.33 Chromosome 8q gains show a highly significant association with reduced 
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survival probability19 and represent an important but later stage in tumour 
progression.33 Chromosome 6 abnormalities consist mainly of gains of 6p or deletions 
of 6q.33 In 1988, Griffin et al was first to describe trisomy of 6p as a cytogenetic 
anomaly in uveal melanoma.17 Multiplications of 6p appear to be associated with a 
good prognosis.32  
 
Gene expression profiling analyses tumour RNA and is a more reliable method of 
detecting mutations in tumours than karyotyping. This method has been 
independently validated and has identified two distinct molecular classes of uveal 
melanoma that strongly predict metastatic death. These were previously 
unrecognized because they are not obviously distinguishable by clinicopathological 
features. Class one tumours are low-grade and have disomy 3.34 Class two tumours 
are associated with liver metastases and a poor prognosis, displaying global down-
regulation of neural crest genes and melanocyte-specific genes on chromosome 3. 
The class two gene expression profile correlates with mutations in the BRCA1- 
associated protein 1 (BAP1) tumour suppressor gene located on chromosome 3, 
which is commonly lost in uveal melanoma.35  
 
In uveal melanoma with poor prognosis, there is a general dysregulation of 
epigenetic modifiers. A recent study comparing disomy (class 1) and monosomy 3 
tumour cells (class 2) found transcriptional downregulation of genes encoding 
epigenetic regulatory enzymes in association with monosomy 3.36 A number of 
signalling pathways are known to be disrupted in uveal melanoma.  
 
In most uveal melanomas, the retinoblastoma and p53 pathways are functionally 
inhibited, although the tumour suppressor genes themselves are rarely mutated.13, 37 
These pathways are inhibited via epigenetic mechanisms and usually as a result of 
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cyclin D1 (in the retinoblastoma pathway) and MDM2 overexpression (in the p53 
pathway). PTEN inactivation is also implicated in the progression of uveal 
melanoma. The mitogen-activated protein kinase/extracellular signal-related kinase 
pathway is essential for mediating cell-cycle progression and is activated in uveal 
melanoma but mutations in candidate oncogenes have not yet been identified.38 
Tumours may also result from the amplification or mutation of an oncogene. It has 
been found that 46% of uveal melanoma and 83% of blue naevi carry mutations in 
the GNAQ gene, a Gq protein alpha subunit.39 
 
2.4 Tumour classification 
The first classification for ciliary body and choroidal melanoma was published in 
1868 in Heidelberg, Germany, by Knapp (1839-1911).40 Knapp divided tumours into 
four stages, according to the presence and absence of symptoms, extraocular 
extension, and distant metastasis. In 1931, Colonel George Callender at the Armed 
Forces Institute of Pathology reported on a series of 111 eyes studied histologically.41 
He found several easily distinguished histological types: spindle-shaped cells, 
epithelioid cells and fascicular cells. Spindle cell tumours are composed of sheets, 
whorls, and irregular arrangements of spindle-shaped cells, with long, oval nuclei. 
He separated them into two divisions. The spindle A cells lack distinct nucleoli and 
have fine chromatin, whereas spindle B cells have more prominent nucleoli and 
coarse chromatin. Epithelioid tumours have a distinct histological appearance similar 
to a fried egg with a large nucleus and small distinct nucleoli. Fascicular tumours 
contain cells that radiate about the centre of a column in a palisade arrangement, 
with an oval nucleus and distinct nucleolus.  
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Callender found that epithelioid cells appear the most malignant, with numerous 
mitotic figures. Patients with tumours consisting of spindle cells unmixed with other 
types have a more favourable outlook that those with epithelioid, fascicular or mixed 
types.42 Large nucleoli and high numbers of mitotic figures are associated with a high 
risk of metastasis.43, 44 Increased pigmentation, macrophage and lymphocyte 
infiltration are also associated with increased metastasis. 
 
In 1986 The Collaborative Ocular Melanoma Study (COMS) standardized size 
definitions of small, medium and large choroidal melanomas in more than forty 
North American centres.45-47 The COMS size distinctions have since been used in 
many studies (Table 2.1):  
 
Table 2.1: COMS tumour size48, 49 
 
 
The seventh edition of the Tumour, Node, Metastasis, classification (TNM7) became 
effective in 201050 and is based on the extent of the primary tumour and the presence 
of any metastases. Size boundaries are based on the COMS classification, also taking 
into account ciliary body involvement and extraocular spread (Figure 2.2). Risk of 
metastatic death is based on a group of 7,369 patients analyzed by the European 
Ophthalmic Oncology Group and is estimated according to ocular tumor stage (with 
 Small Medium Large 
Tumour height (mm) 1.5-2.4 2.5-10 >10 
Largest basal diameter (mm) 5-16 <16 >16 
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categories having the same prognosis grouped into the same stage); regional lymph 
node involvement; and the presence of known metastases. Based on anatomic 
classification, the ten-year Kaplan-Meier estimate of survival for T1 tumours is 89% 
(Figure 2.3).51  
 
 
Figure 2.2 (above): TNM tumour size32 
 
 
Table 2.2 (below): Overview of the classification of malignant ciliary body and 
choroidal melanoma in the seventh edition of the TNM classification51 
Tumour extension outside the choroid 
Size category,  
see Figure 2.1 None Ciliary body only 
Extraocular only, 
<5 mm 





T1 T1a (stage I) T1b (stage IIA) T1c (stage IIA) T1d (stage IIA)  
T2 T2a (stage IIA) T2b (stage IIB) T2c (stage IIIA) T2d (stage IIIA)  
T3 T3a (stage IIB) T3b (stage IIIA) T3c (stage IIIA) T3d (stage IIIB)  
T4 T4a (stage IIIA) T4b (stage IIIB) T4c (stage IIIB) 
T4d (stage 
IIIC) T4e (stage IIIC) 
Abbreviation: TNM, tumour, node, metastasis 
Clinical and pathological classifications are identical; if N1 or M1, the stage is IV regardless of size category 
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Figure 2.3 (above): Kaplan–Meier survival curves displaying melanoma-related 
mortality for 5,403 patients with known tumour size, ciliary body, and extraocular 
extension (stage I–IIIC), and for 224 patients with newly detected metastatic uveal 
melanoma (stage IV)51 
 
2.5 Metastasis 
Invasion and metastasis are properties unique to cancer cells and lead to the direct 
extension of the tumour outside its tissue of origin. Metastasis refers to the transfer of 
malignant cells from one site to another not directly connected with it.11 The first 
account of metastases from an ocular melanoma was described in the eighteenth 
century in the artist Sir Joshua Reynolds (1723-1792), who died at the age of sixty-
seven, eighteen months after losing vision in his left eye.52 Circulating tumour cells 
penetrate capillaries and venules to invade distant sites. Lymphatic spread is also 
common, however the eye has no lymphatic drainage and uveal melanomas 
metastasise via haematogenous spread, usually to the liver. A number of steps are 
required for malignant cells to establish a metastasis:11 
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 Invasion of the basement membrane underlying the tumour 
 Movement through the extracellular matrix 
 Penetration of vascular (or lymphatic) channels 
 Survival and cell cycle arrest within the circulating blood or lymph 
 Exit from the circulation into a new tissue site 
 Survival and growth as a metastasis, a process that involves angiogenesis 
 
Calculation of melanoma doubling time suggests that most uveal melanoma 
metastases are initiated up to five years before diagnosis and primary treatment.53 
Hepatic metastases occur early in the development of uveal melanoma at a time 
when the primary tumour may be too small to be detected clinically.53, 54 Metastases 
may remain dormant for many years before becoming detectable. It is debated 
whether this dormancy represents a balance between cell growth and cell death or 
whether tumour cells are in cell cycle arrest. 
 
Circulating tumour cells can be found in patients with uveal melanoma before any 
signs of clinically advanced disease.55, 56 Cells disseminated early might persevere as 
clinically dormant metastasis, later giving rise to distant recurrences.39 Uveal 
melanoma cells can remain dormant for longer than a decade, and metastasis-related 
deaths can occur more than forty years after diagnosis.57 This implies that metastatic 
cells may be quiescent in the liver for long periods before switching to an accelerated 
pattern of growth.58 A large meta-analysis of 5,433 patients from fifty-three studies 
looking at the detection of circulating tumour cells in patients with melanoma found 
insufficient evidence to conclude that circulating melanoma cells are a biomarker 
reliable enough to be clinically useful.59 
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Malignant cells spread to distant sites by a process that requires invasion of the 
circulation. However, most tumour cells do not survive their journey in the 
bloodstream, and less than 0.1% remain to establish a new colony.11 Surviving cells 
attach to endothelial cells, causing retraction of the endothelium to expose the 
basement membrane. The tumour cells subsequently extravasate and grow in 
response to autocrine and local growth factors.  
 
2.6 Vascular endothelial growth factor 
Angiogenesis, or the formation of new blood vessels, is a complex process that occurs 
in normal physiology as well as disease. In 1983 Dvorak et al isolated a polypeptide 
they called vascular permeability factor.60 The same polypeptide was purified by 
Ferrara six years later and was named vascular endothelial growth factor (VEGF).61 
VEGF is involved in angiogenesis and lymphangiogenesis during embryonic and 
postnatal development. It also plays a role in normal adult physiological processes 
including ovarian angiogenesis, tissue regeneration, haematopoietic stem cell 
survival, erythropoietin regulation and endochondral bone formation.62 Pathological 
processes such as neoplastic, haematological, ocular, inflammatory and ischaemic 
diseases also involve VEGF. In fact, so far-reaching are the processes involved that 
angiogenesis has been labelled an “organising principle” in biology and medicine.63 
 
The VEGF gene family consists of numerous members including VEGF-A, -B, -C, -D 
and placental growth factor. The most abundant and mitogenic member is VEGF-A, 
a multifunctional cytokine. VEGF-A increases microvascular permeability,60 induces 
endothelial cell migration and division, reprogrammes gene expression, promotes 
endothelial cell survival, prevents senescence, and induces angiogenesis.64 The 
expression, availability, and activity of VEGF-A is modulated by several mechanisms 
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including hypoxia, oncogene and tumour suppressor dysregulation, transcription 
factors, inflammatory mediators, and mechanical forces.62 
 
VEGF-A is widely expressed by tumour cells and its action is primarily targeted 
towards vascular endothelial cells. In tumour angiogenesis, tumour cells and the 
surrounding tumour stroma release VEGF. Both uveal melanoma cells and the 
overlying retina produce VEGF-A, as well as other factors that promote invasion and 
metastasis.65, 66 This may indicate an autocrine-type induction of VEGF-A by the 
tumour on surrounding tissue.67 Tumour vascular endothelial cells express several-
fold higher levels of VEGF receptors62 compared to normal vascular endothelial cells.  
 
The regulation of VEGF-A in uveal melanoma is mainly controlled by hypoxia and 
involves the HIF-1! pathway.68 Phenotypically more aggressive tumours of larger 
height and basal diameter show higher levels of VEGF. Cell lines from uveal 
melanoma secrete several angiogenic factors including VEGF-A, which has been 
found in the aqueous and vitreous humour of affected eyes.69, 70 A study of VEGF-A 
concentrations in the aqueous humour of seventy-four untreated uveal melanomas 
found an almost three-fold increase compared to controls.67 Serum VEGF-A levels are 
increased in the presence of metastases.68 
 
Tumour growth does not occur continuously but rather in periods of rapid growth 
after dormancy. The concept of an “angiogenic switch” was postulated whereby the 
process of neovascularization of tumour cells allows rapid growth beyond the 1-2 
mm limits of a non-vascularised metastasis.8, 71, 72 The angiogenic switch signals the 
rate-limiting transformation from hyperplasia to neoplasia and is regulated via 
environmental and genetic factors.8, 12 Sustained angiogenesis in uveal melanoma has 
been demonstrated by increased production of VEGF inducers in tumour cells and 
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accompanying inflammatory cells via upregulated expression of VEGF, IGF-1, IGF-
1R, and raised levels of HIF-1!.13 
 
Tumour vessels stimulated by VEGF are structurally and functionally irregular, with 
necrotic cells, disordered blood flow, and increased permeability. Stasis and 
turbulent flow lead to further tumour hypoxia and consequent VEGF expression.70 
The eye has no lymphatic drainage and uveal melanoma is a vascular tumour with 
almost exclusively haematogenous metastasis, making it a potential target for anti-
angiogenic therapy. 
 
A number of angiogenesis inhibitors have been approved for the treatment of cancer. 
The earliest drugs approved were bevacizumab (Avastin, Genentech/Novartis), a 
ligand-trapping monoclonal antibody, and two kinase inhibitors - sorafenib 
(Nexavar, Bayer) and sunitinib (Sutent, Pfizer) - targeting the VEGF receptor 
(VEGFR) tyrosine kinases, principally VEGFR2, type 2. Bevacizumab is a 
recombinant humanized monoclonal antibody targeting VEGF-A and all its isoforms. 
The United States Food and Drug Administration (FDA) approved it in 2004 for the 
treatment of advanced metastatic colorectal carcinoma based on a large, randomised 
phase III trial involving 813 patients which showed a five-month survival benefit 
when bevacizumab was added to standard chemotherapy versus chemotherapy 
alone.73 It is also used in combination with chemotherapy in the treatment of non-
small cell lung cancer and breast cancer. Sorafenib and sunitinib have both been 
approved for the treatment of renal cell carcinoma, a highly vascular tumour. 
 
Despite initial survival benefits, these VEGF inhibitors are failing to produce 
longstanding inhibition of tumour growth. Transitory improvements with a period 
of clinical benefit are followed by progression of the disease, suggesting an emergent 
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resistance to anti-angiogenic therapy. Two modes of resistance have been proposed: 
“evasive resistance”, with up-regulation of alternative pro-angiogenic pathways, and 
intrinsic or pre-existing non-responsiveness due to genetic ablation of the hypoxic 
response or the VEGF/VEGFR pathways.74 Monotherapy with a single angiogenesis 
inhibitor may not be sufficient75 and combining anti-angiogenic therapy with anti-
invasive and anti-metastatic drugs may be a way to circumvent this problem. 
 
Anti-VEGF treatments have revolutionised the management of many ocular 
conditions. VEGF has been implicated in the pathophysiology of multiple 
neovascular processes in human ocular conditions. Intravitreal bevacizumab has 
been studied in diseases such as age-related macular degeneration (ARMD), 
retinopathy of prematurity,76 diabetic retinopathy, radiation retinopathy and retinal 
vein occlusion. Ranibizumab (Lucentis, Novartis / Genentech) is a Fab antibody 
fragment that binds to all isoforms of VEGF. It is US FDA-approved for use in the 
eye and its efficacy in the treatment of ARMD has been demonstrated in large 
prospective, randomized controlled trials.77  
 
There have been case reports of bevacizumab as a treatment for intraocular tumours. 
A fifty-seven year-old woman with stage IV oestrogen receptor negative breast 
carcinoma treated with chemotherapy developed a choroidal metastasis that was 
treated with a high dose of bevacizumab (4 mg), resulting in a dramatic decrease in 
tumour size.78 Another case series reported three patients with choroidal melanoma 
initially misdiagnosed as choroidal neovascular membranes and treated with courses 
of bevacizumab at the standard dose of 1.25 mg/0.05 mL.79 The patients were treated 
with courses of either four or five bevacizumab injections, with two showing 
resolution of subretinal fluid. Two patients eventually underwent enucleation and 
histology demonstrated the formation of a subretinal fibrotic membrane overlying 
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the tumour. This feature had not been reported in a review of the histopathologic 
features of 1,527 globes with uveal melanoma.80 Dose-dependent reduction in size of 
intraocular melanoma in a murine model has been demonstrated after 
intraperitoneal injections of bevacizumab.81 
 
While there have been case reports of the use of bevacizumab in the treatment of 
uveal melanoma, to date no controlled studies have been published. There are many 
trials currently studying new angiogenesis inhibitors for advanced metastatic 
disease. A multicentre phase-II study involving 40 patients with inoperable stage III 
or IV metastatic uveal and cutaneous melanoma evaluated the VEGF trap aflibercept 
(Eylea, Regeneron). Half the patients treated (n=20) demonstrated four months of 
progression-free survival, and overall survival at one year was 56.4% compared to a 
predicted survival of 36%.82 Early results are promising, and further study on 
angiogenesis inhibitors is warranted. 
 






3.1  Epidemiology 
Uveal melanoma is the most common intraocular malignancy and has the potential 
to cause blindness and death through metastasis. It is the most common non-
cutaneous melanoma. The mean age-adjusted incidence of uveal melanoma has 
remained stable for decades, with rates about six per million per year in the United 
States.83, 84 Men are at slightly higher risk than women, and peak incidence occurs at 
the age of seventy years, although individuals of any age can be affected.  
 
Uveal melanoma usually occurs sporadically in the absence of obvious genetic 
predisposing factors. Unlike cutaneous melanoma, it is very rare for uveal melanoma 
to occur in families, although a handful of case reports have described familial uveal 
melanoma, usually affecting only two relatives. Affected families tend not to show 
features of a genetic predisposition, such as involvement over many generations, 
earlier age at diagnosis, bilateral involvement, multiple primary tumours, and 
phenotypic associations.32 These cases could in fact be explained by chance alone, 
given that the likelihood of uveal melanoma occurring in two individuals of a family 
of five is one in ten million.85 In 1905, Parsons described a family with a four-
generation history of uveal melanoma and breast cancer. Immunohistochemical 
investigations of museum specimens of enucleated eyes from this family in the late 
20th century showed mutant p53.86 It is likely that this family is an early example of 
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the Li-Fraumeni syndrome, an autosomal dominant cancer predisposition syndrome 
owing to a germline p53 mutation.32 
 
3.2  Phenotypic associations 
Phenotypes associated with uveal melanoma include fair skin, light iris colour, 
numerous cutaneous naevi, congenital ocular melanocytosis, oculodermal 
melanocytosis, uveal melanocytoma, familial atypical mole and melanoma 
syndrome, dysplastic cutaneous naevi, familial cutaneous melanoma and 
neurofibromatosis type one.6, 87 
 
Oculodermal melanocytosis describes congenital hyperpigmentation of the skin, 
episclera, orbit and meninges. Affected individuals also have excessive melanocytes 
in their uveal tract. This condition occurs thirty-five times more frequently in 
Caucasians with uveal melanoma compared to the general population.88 Followed for 
life, it is estimated that one in four hundred Caucasians with oculodermal 
melanocytosis will develop uveal melanoma.89 Consequently it is recommended that 
affected individuals are examined annually for signs of uveal melanoma. Patients 
with ocular and oculodermal melanocytosis who develop uveal melanoma have 
double the risk of metastasis compared to those without melanocytosis.90  
 
Neurofibromatosis type one (NF-1) is an autosomal dominant, multi-system disorder 
of neural crest-derived cells and has an incidence of one in 3,000. Affected 
individuals have excess cutaneous melanocytes, which manifest in the skin as café-
au-lait spots, in the iris as Lisch nodules and in the choroid as naevi. 
Neurofibromatosis is also associated with neural crest-derived cell malignancies such 
as malignant schwannoma, phaeochromocytoma, and medullary carcinoma of the 
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thyroid gland.91 The NF-1 tumour suppressor gene is located on chromosome 17q11 
and is known to regulate growth in neural crest cells such as melanocytes.92 About 
twenty cases have been reported in the literature of affected patients with uveal 
melanoma.32 This could however be coincidental; in one study, only one tumour in 
thirty-eight uveal melanomas studied contained a deletion in the NF-1 locus, with a 
resultant lack of neurofibromin expression.92 
 
3.3  Clinical presentation 
Patients may have their melanoma diagnosed during a routine eye examination, but 
the majority have visual symptoms which include blurred vision, photopsia, and 
visual field changes.93 The classic appearance of a choroidal melanoma is a dome-
shaped grey mass with surrounding exudative retinal detachment (Fig 3.1, 3.2). A 
“collar-stud” appearance occurs if the tumour breaks through Bruch’s membrane. 
The tumour is usually pigmented and has overlying orange lipofuscin, which sits at 
the level of the retinal pigment epithelium. Anterior or large melanomas may have 
prominent episcleral feeder vessels. Choroidal folds, haemorrhage, rubeosis, 
secondary glaucoma, cataract and uveitis may also occur if the tumour is large.  
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Figure 3. 1: (above) Large peripheral choroidal melanoma (courtesy of Professor 
ACB Molteno) 
 
Figure 3. 2: (above) Large posterior pole choroidal melanoma with exudative 
retinal detachment involving optic disc (courtesy of Professor ACB Molteno) 
 
A number of lesions may mimic the appearance of a choroidal melanoma and it is 
important to consider other likely diagnoses. The large randomised Collaborative 
Ocular Melanoma Study (COMS) has shown that the misdiagnosis rate of large 
choroidal melanomas based on clinical examination, photographs, fluorescein 
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fundus angiography and ultrasound scan is 0.48%.94 However, selection criteria for 
the study itself was narrow, and difficult cases such as those with media opacities, 
ciliary body melanomas and pre-existing malignancies were excluded. 
 
The differential diagnosis of a uveal melanoma is extensive.95 Haemorrhagic 
processes are common and can cause confusion. Subretinal haemorrhage from 
neovascular age related macular degeneration or a ruptured macroaneurysm may 
appear as a pigmented subretinal mass. Patients will usually have signs of macular 
degeneration in the other eye or a history of hypertension. A prominent vortex vein 
ampulla appears as a small, smooth brown dome-shaped lesion that disappears with 
external pressure on the eye. Congenital hypertrophy of the retinal pigment 
epithelium appears flat and pigmented with lacunae and well-defined margins. A 
melanocytoma is deeply pigmented with a feathery border and usually lies at the 
optic disc. 
 
Up to 30% of uveal melanoma are amelanotic and there are a number of other lesions 
to consider when making this diagnosis.95 A choroidal metastasis is usually non-
pigmented and appears at the posterior pole. There may be multiple or bilateral 
masses and the patient may not have a history of cancer. These tumours never have a 
collar-stud appearance.95 A choroidal haemangioma appears as an orange or pink 
dome-shaped mass at the posterior pole. Other non-pigmented lesions include 
choroidal granulomas which are small pale lesions associated with sarcoid and other 
uveitic conditions. Benign ciliary body lesions can mimic ciliary body melanoma. Iris 
and ciliary body cysts are not uncommon. Other rare ciliary body tumours include 
medulloepithelioma, adenocarcinoma, adenoma neurolemmoma, and leiomyoma.6 
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3.4  Naevi and small tumours 
It is estimated that fewer than one in 8,000 naevi undergo malignant transformation 
to uveal melanoma.96 A number of factors that predict growth in small choroidal 
melanocytic tumours have been identified. These include tumour thickness greater 
than 2 mm, posterior tumour margin touching the optic disc, visual symptoms 
(photopsia), orange pigment (lipofuscin), and the presence of subretinal fluid 
(Figures 3.3-3.5).97 Acoustic hollowness and absence of a halo are classic 
ultrasonographic features. Tumours with more risk factors are more likely to grow, 
with a median hazard ratio for those with one or two risk factors of three, rising to 
twenty-one for the presence of all seven factors.98  
 
Figure 3. 3: Peripheral naevus with overlying drusen. The patient is asymptomatic, 
there is no subretinal fluid or lipofuscin and thickness on ultrasound is 3.5 mm, 
giving one risk factor for growth. Image courtesy of Professor ACB Molteno 
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Figure 3. 4: (above) Choroidal melanoma with subretinal fluid and margin 
involving the optic disc (courtesy of Professor ACB Molteno) 
 
Figure 3. 5: Peripheral small choroidal melanoma with drusen, lipofuscin and 
subretinal fluid (courtesy Professor ACB Molteno) 
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3.5  Ancillary testing 
Ultrasonography is the most useful ancillary test to aid diagnosis. Choroidal 
melanoma often show medium to low internal reflectivity with smooth attenuation 
on A-scan. Vascular pulsations may also be seen within the tumour. B-scan 
ultrasonography can provide useful information on the size and characteristics of 
choroidal or ciliary body melanoma. Melanomas are typically solid masses with low 
to medium internal reflectivity and a biconvex cross-sectional shape. Tumours 
display acoustic hollowing, with an acoustic quiet zone at the tumour base. 
Classically there is underlying choroidal excavation with shadowing of subjacent 
orbital soft tissue. 
 
Choroidal melanomas characteristically display autofluorescence due to the presence 
of lipofuscin. Spectral domain optical coherence tomography (SD-OCT) allows 
impressive resolution of retinal and choroidal architecture (Fig 3.6).99 It is a 
potentially useful modality for tumours that are too small to be identified by 
conventional ultrasonography and is ideal for small (<3 mm) posterior pole tumours. 
Thickness measurements are on average 55% percent thinner using SD-OCT 
compared to ultrasonography.100 SD-OCT features of small choroidal melanomas are 
not always present, but include “shaggy photoreceptors” which indicate chronicity 
of retinal detachment, loss of external limiting membrane, and in some tumours loss 
of the inner segment-outer segment junction, irregularity of the inner plexiform 
layer, intraretinal oedema and irregularity of the ganglion cell layer (Fig 3.7).100 
Image quality is limited by patient cooperation and media opacities. SD-OCT is also 
operator-dependent and cannot image thick tumours.  
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Figure 3. 6: Nomenclature for normal anatomic landmarks seen on spectral-domain 
optical coherence tomography proposed and adopted by the International 
Nomenclature for Optical Coherence Tomography Panel99 
 
 
Figure 3. 7: Colour photos and SD-OCT of choroidal melanoma showing (B and E) 
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Fluorescein fundus angiography (FFA) is not routine but may provide additional 
information and can identify masquerades such as choroidal neovascular 
membranes. There are no pathognomic features of choroidal melanoma on FFA, but 
large melanomas characteristically have intrinsic vascularization, also known as a 
“double circulation”, referring to the simultaneous fluorescence of the retinal and 
choroidal vasculature within the tumour. Extensive leakage is often present, 
characterized by multiple pinpoint leaks (“hotspots”) at the level of the retinal 
pigment epithelium.  
 
Computerized tomography (CT) scanning is more expensive than ultrasonography 
and has a limited role in the diagnosis of uveal melanoma. Choroidal melanomas 
show enhancement with contrast, which may differentiate it from a solid tumour or 
exudative retinal detachment. CT scanning will also detect calcification, a feature of 
choroidal osteomas. 
 
Magnetic resonance imaging (MRI) scanning provides greater diagnostic value than 
CT but is less sensitive than ultrasonography. It is useful for detecting ciliary body 
melanomas and posterior extrascleral tumour extension.102 Most choroidal and ciliary 
body melanomas appear hyperintense relative to the vitreous on T1-weighted 
images and hypointense relative to the bright vitreous humour on T2-weighted 
images. 
 
Positron emission tomography (PET) scanning is a relatively new modality that is 
increasingly being used to image uveal melanoma. PET scanning utilizes a 
radioactive form of glucose (18-fluoro-2-deoxyglucose, FDG) that taken up by highly 
metabolically active cells such as malignant tumour cells. It has low sensitivity and is 
expensive but can be useful to detect metastases. PET/CT scanning combines the 
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metabolic findings of PET with the anatomic characterization of CT. Some centres 
use PET scanning for baseline systemic evaluation. In a study of fifty patients, neither 
T1 tumours or small COMS choroidal melanomas were identified by PET/CT.103 Not 
all tumours larger than the 4 mm resolution limit were detected, confirming that high 
metabolic activity is integral to tumour detection using this modality. 
 
3.6  Systemic evaluation 
The choroid has the highest blood flow in the body and uveal melanoma is 
remarkable for haematogenous spread to the liver. Metastatic disease diagnosed 
using serum liver enzymes and liver ultrasound scanning is uncommon at diagnosis 
of the primary tumour, accounting for only 1-2% of patients.104 There is variation 
between centres in the level of screening undertaken to detect systemic disease. Some 
ophthalmologists perform a chest x-ray, liver ultrasound and serum liver enzyme 
panel in addition to a referral to an oncologist. Other centres screen for metastases in 
certain situations such as large tumour thickness to avoid unnecessary investigations 
and false-positive results.105 
 
3.7  Treatment options 
It has long been known that for comparably-sized uveal melanomas, survival is 
independent of the method of treatment of the primary tumour.106, 107 Despite the fact 
that most aggressive tumours have metastasized prior to diagnosis, failure to achieve 
local control is associated with increased risk of tumour-associated death.108 There are 
many treatment options shown to achieve local control, and patient- and hospital-
based factors determine the most appropriate treatment for a given patient. Factors 
considered when deciding the most appropriate treatment include access to 
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treatment modalities, tumour location, size, visual acuity, intraocular pressure, 
growth rate, patient age, general health and the status of the fellow eye. 
Radiotherapy is the most common organ-sparing treatment for choroidal and ciliary 
body melanoma. Treatment options will be further discussed in detail in the 
following chapters. 
 
3.8  Prognosis 
Uveal melanoma is an aggressive cancer. Overall, there is a 50% chance of survival, 
but prognostication can be further stratified for an individual to do much better or 
worse. Survival prognosis correlates with clinical stage (TNM), histological grade 
and genetic type of melanoma. The single strongest indicator of prognosis in 
metastatic disease is the largest diameter of the largest metastasis, which has been 
incorporated into the current TNM anatomic classification (see Table 2.2). 
 
As outlined in the previous chapter, multiple anatomic, histologic and molecular 
features have been identified that are poor prognostic indicators. Larger tumour size, 
ciliary body location, extrascleral extension, epithelioid cell type, and numerous 
mitotic figures all increase the risk of metastatic disease.41, 109, 110 Indicators of 
aggressive behaviour are chromosomal abnormalities involving monosomy 3 and 
gain of 8q.15, 20, 28, 34, 111 Almost all metastatic deaths occur in patients whose melanoma 
shows partial or complete loss of chromosome 3 on cytogenetic testing.20 
 
Epigenetic mechanisms such as histone modifications, DNA methylation, 
hydroxymethylation and non-coding RNA are critical to the regulation of the cell 
cycle, gene expression, apoptosis, phenotypic plasticity and other biologic functions 
in both normal and cancer cells. In 2004, Onken et al demonstrated that primary 
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uveal melanomas cluster into two distinct molecular classes based on gene 
expression profiling. They were able to separate uveal melanomas into low-grade 
(class one) and high-grade (class two) groups and showed that down-regulation of 
three genes (PHLDA1, FZD6 and ENPP2) accurately predicted metastatic death.111 
The prognostic accuracy of these tests were subsequently confirmed by independent 
groups.112, 113 
 
The COMS trial of large melanoma studied 1,003 patients and found that of 435 
patients who had died, 62% had histologically confirmed metastatic melanoma at 
death and another 21% had suspected metastases on the basis of imaging and tests 
but had no histological confirmation.114 The overall five- and ten-year metastasis rates 
of all patients enrolled in the large and medium COMS trials (2,320 patients) were 
25% and 34% respectively.115 Long-term follow up of 289 patients in Finland with 
posterior uveal melanoma showed melanoma-related mortality rates of 31% by five 
years, 45% by fifteen years, 49% by twenty-five years, and 52% by thirty-five years.116 
 
Once metastatic disease has been diagnosed, in the largest unselected series of 
patients, the median survival time is 3.6 months, with a death rate of 80% at twelve 
months, and 92% at two years.115 Poor prognostic factors for survival time after 
detection of metastasis include older age, male gender, tumour symptoms, tumour 
diagnosis following symptoms, low Karnofsky index,117 short metastasis-free 
interval, hepatic involvement, numerous anatomic sites for metastasis, larger 
proportion of liver involved, and elevated liver enzymes.118, 119  
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3.9  Surveillance of metastatic disease 
Tumour dormancy refers to the disease-free period between clinical cure of the 
primary cancer and its subsequent local recurrence or distant metastasis. Based on 
melanoma doubling time, it has been calculated that most uveal melanoma 
metastases are initiated within five years before primary treatment.53 Metastatic cells 
can remain dormant for longer than a decade, and 40-50% of patients with uveal 
melanoma have a greater than ten year disease-free interval.39  
 
The liver is the predominant organ involved in metastatic disease in 90% of cases and 
median survival after diagnosis is approximately eight months.117 With concurrent 
liver imaging and serum alkaline phosphatase, chest x-ray screening does not yield 
additional benefit in diagnosing metastatic disease.117 A study of patients with 
metastatic uveal melanoma found that the chest radiograph and liver ultrasound 
were 100% specific but had sensitivities of only 2% and 14% respectively.120 Numbers 
were small however: only 40 patients had a liver ultrasound and 223 had a chest x-
ray.  
 
Serum liver enzyme screening has low sensitivity and positive predictive value.122 
Sensitivity indicates the probability of having raised liver enzymes in the presence of 
metastatic disease. Positive predictive value is the probability of metastatic disease in 
patients with raised liver enzymes. Isolated or combined liver function tests for 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl 
transpeptidase (GGT) and lactate dehydrogenase (LDH) are not helpful in the 
detection of early metastases.122 Analysis of COMS patients with medium and large 
tumours who underwent screening for metastatic disease found that testing an 
individual liver function test (alkaline phosphatase, ALT, AST, GGT, LDH, or 
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bilirubin) provided high specificity (98%) but low sensitivity (0-19%) in detecting 
metastatic disease.123 False positive results may induce an unnecessary request for 
liver imaging. These markers do however have a relatively high negative predictive 
value, which may be of reassurance in the case of a negative test result. With normal 
liver enzymes, there is a 2.5% chance of metastatic disease being present.122 
 
A number of serum biomarkers have been identified that are increased before clinical 
diagnosis of metastatic disease. These include S100 beta, osteopontin, melanoma 
inhibitory antigen, and vascular endothelial growth factor.124 Insulin-like growth 
factor-1 has been shown to decrease with the development of uveal melanoma 
metastases six months prior to clinical detection and is a promising biomarker for 
metastatic disease.125 
 
Screening is “a health service in which members of a defined population… are asked a 
question or offered a test to identify those individuals who are more likely to be helped than 
harmed by further tests or treatments to reduce the risk of disease or its complications”.126 In 
1968, the World Health Organisation proposed principles of screening which have 
been adapted for New Zealand by the National Health Committee.126 They 
recommend that eight criteria be used to assess screening programmes (Table 3.1). 
 
Screening for metastatic disease in patients with uveal melanoma is controversial for 
a number of reasons. There is no good screening test for metastatic disease.120 Early 
detection of metastasis does not increase survival, but does lengthen the interval 
between metastasis and death due to detection bias. Micrometastases may occur 
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Table 3.1: Criteria for assessing a screening programme126  
Criteria for assessing a screening programme 
 The condition is a suitable candidate for screening 
 There is a suitable test 
 There is an effective and accessible treatment or intervention for the condition identified 
through early detection 
 There is high quality evidence, ideally from randomized controlled trials, that a 
screening programme is effective in reducing mortality or morbidity 
 The potential benefit from the screening programme should outweigh the potential 
physical and psychological harm (caused by the test, diagnostic procedures and 
treatment) 
 The health care system will be capable of supporting all necessary elements of the 
screening pathway, including diagnosis, follow-up and programme evaluation 
 There is consideration of social and ethical issues 
 There is consideration of cost-benefit issues 
 
The potential benefits of screening for metastatic disease include reassurance for 
those with true negative test results, and knowledge of their situation for people with 
true positive results. Patients want to be informed of their prognosis, even if it is 
poor.127 Although earlier treatment can be offered to patients with positive results, 
there is no cure for metastatic uveal melanoma. Disadvantages of screening include 
longer periods of morbidity for patients whose prognosis is unaltered, resource costs, 
anxiety and risks associated with further investigations and treatment.126 
 
Periodic screening for metastases is thought to be beneficial when effective treatment 
is available or when patients are eligible to be candidates for clinical trials of 
promising treatment.117, 120, 123 A study of 298 patients with uveal melanoma 
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investigating their reasons for accepting cytogenetic testing and their reactions to 
results received found that the main benefit perceived by patients was that they 
would have greater control and that screening for metastatic disease and early 
treatment might enhance chances of survival.128 This was despite counselling that 
prognostication, screening and treatment are unlikely to prolong life. They found 
that almost all patients with uveal melanoma desire cytogenetic prognostication, and 
the only patient who regretted her decision had declined testing. 
 
3.10  Treatment of metastatic disease 
There are no prospective, randomised phase III clinical trials on treatment for 
metastatic uveal melanoma.118, 129 Augsburger et al129 performed a literature search of 
articles on the effectiveness of treatment for metastatic uveal melanoma over a 
twenty-eight year period to June 2008. Of eighty identified publications, there were 
twenty-five phase I or II prospective clinical trials. 
 
Treatment of metastatic disease requires aggressive intervention: metastectomy130 
(surgical resection of metastatic tumours), systemic chemotherapy131 or regional 
therapies such as intrahepatic arterial chemotherapy132 and either embolization or 
chemoembolization133 of hepatic metastases. Median survival times in reported 
retrospective and prospective case series of metastatic uveal melanoma treated with 
these interventions range from 5.2 to 29.4 months.129  
 
Chemotherapy at present cannot stop the evolution of metastases. Chemoresistance 
is a major problem in oncology, illustrated by the fact that only one cancer in two is 
in long-term remission with chemotherapy.33 The multi-drug resistance phenotype 
expressed in uveal melanomas is complex and can vary considerably in its 
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components from one melanoma to another A study of ninety-one consecutive 
patients who died of metastatic uveal melanoma found a median survival of 8.4 
months from diagnosis for unselected patients and twelve months for those who 
received systemic chemotherapy.117 
 
The treatment of metastatic disease is controversial. Uveal melanoma is a rare disease 
and patient groups are highly selected before undergoing interventions to prolong 
survival with metastatic disease. Poor patient numbers mean insufficient power to 
make claims that any treatment can cause a clinically and statistically significant 
lengthening of overall survival compared to no treatment at all.129 Furthermore, there 
is likely to be a strong submission bias, where authors fail to submit negative or 
inconsequential reports, resulting in only positive studies in the literature.118 No 
randomized trials of treatment for metastatic uveal melanoma have been undertaken 
due to the rarity of the disease and lack of ability to achieve power. 
 
By the time the primary tumour is detected, uveal melanoma is already a metastatic 
disease. Multiple studies have demonstrated late-onset metastatic disease up to forty 
years after successful enucleation of the primary tumour.116, 134 Quiescent tumour cells 
are resistant to conventional therapies that target rapidly dividing cells. Tumour 
dormancy is a poorly understood and unpredictable process. Maintaining tumour 
cells in their dormant state could however be considered an acceptable clinical 
endpoint if future therapeutic modalities allow prolongation of dormancy and 
prevent the development of clinically significant metastatic disease and death.135   
 
There has however been some success in prolonging survival with surgical resection 
of hepatic metastases.136-138 A large study at the Institut Curie followed 798 patients 
with metastatic uveal melanoma.136 Median survival was 4 months from diagnosis, 
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which increased to 8 months for patients who were treated with chemotherapy. A 
total of 255 patients underwent hepatic resection, which extended survival to 14 
months. Survival was longer in patients who had a complete resection, fewer 
metastatic nodules, and were longer to develop metastases. Those with miliary 
lesions did worse. A smaller series of 35 patients found that those who underwent 
partial hepatectomy survived 3.7-fold longer than comparable patients who did not 
undergo surgery. Survival was longer in patients with one to five metastastic 
nodules and complete resection.137 In another study, twelve patients were treated 
with partial hepatectomy, of which eleven relapsed into metastatic disease with a 
median survival of twenty-four months.139 In 188 patients with a predicted 35% five-
year survival, ninety (48%) developed metastases a median of eighteen months after 










4.1  Enucleation 
Traditionally, uveal melanoma was treated by enucleation of the affected globe. In 
1882, Ernst Fuchs (1851-1930) wrote that all intraocular melanomas were treated by 
enucleation, and untreated cases were only in the “older literature”.140 Enucleation 
remained the mainstay of treatment until the late 1970s, when doubt was cast on its 
efficacy. Zimmerman et al observed a peak in mortality in the second postoperative 
year following enucleation, and in a watershed article, postulated that manipulation 
of the globe during enucleation caused seeding of the tumour, accelerating metastatic 
death.141, 142 They advocated a “no touch” technique for enucleation143 that avoided 
putting pressure on the globe. This theory later became known as the “Zimmerman-
McLean-Foster Hypothesis” and stimulated widespread research into alternative 
treatments for uveal melanoma, including the Combined Ocular Melanoma Study 
(COMS). 
 
Enucleation can be performed under local or general anaesthesia. It allows for the 
complete histologic examination of the eye and optic nerve and involves removal of 
the entire globe while preserving other orbital tissues. The surgeon must take care to 
avoid penetrating the globe during surgery and must handle the globe gently to 
minimize the risk of disseminating tumour cells. An orbital implant of sufficient 
volume is centred within the orbit and covered with Tenons and conjunctiva. 
Fornices should be deep enough to hold a prosthesis. 
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Enucleation is still performed for large uveal melanoma when there is no hope for 
useful vision with conservative treatment,144 when conservative forms of therapy fail, 
or on patient request. Features likely to result in primary or secondary enucleation 
include:145 
 Old age 
 Tumour diameter exceeding 17 mm 
 Tumour height greater than 10 mm 
 Extensive involvement of optic disc, ciliary body, iris or angle 
 Bulky extraocular extension 
 Diffuse tumour growth 
 Extensive retinal invasion or perforation 
 
Compared to conservative forms of therapy, enucleation has not been shown to offer 
any survival advantage and does not accelerate metastatic death. The COMS group 
found that pre-enucleation radiotherapy does not improve survival.146 Primary 
enucleation is performed in about a third of patients with uveal melanoma and 
secondary enucleation is required in about 10% of cases initially treated 
conservatively.147 Orbital tumour recurrence is rare if visible extraocular extension is 
not present at the time of enucleation.145  
 
Intraoperative complications of enucleation include removal of the wrong eye, 
anaesthetic complications from general anaesthesia (airway compromise, adverse 
drug reactions) or retrobulbar anaesthesia (globe perforation, brainstem anaesthesia, 
arterial injection of anaesthetic, orbital haemorrhage); bradycardia or asystole from 
stimulation of the oculo-cardiac reflex, orbital haemorrhage, incomplete enucleation 
if the eye is long or hypotonous, damage to the optic chiasm (and visual field of 
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contralateral eye) due to optic nerve stretch and extraocular muscle or nerve damage 
(resulting in poor motility of the prosthesis). Postoperative complications include 
infection, wound dehiscence, conjunctival cysts, implant migration or extrusion, 
socket contracture, ptosis, lash margin entropion, deep sulcus and complications 
associated with particular implants (e.g. hydroxyapatite implants).148, 149 
 
4.2  Tumour biopsy  
With recent advances in molecular biology and genetics, obtaining tumour tissue for 
prognostication has become increasingly desirable as an adjunct to globe-conserving 
treatments. There are several different intraocular tumour biopsy techniques. These 
include aqueous tap, fine needle aspiration biopsy (FNAB) performed trans-sclerally 
or trans-vitreally, different vitrectomy approaches, endoretinal biopsy and external 
resection. 
 
Indications for biopsy vary between centres with some units performing more 
biopsies than others. The main indication for FNAB is molecular prognostication, 
although it is also useful in the diagnosis of intraocular masses with atypical clinical 
findings.150, 151 It can also be useful in suspected metastasis with an unknown primary 
malignancy. Although 10% of patients who present with uveal melanoma have a 
history of a primary malignancy elsewhere, about a third of patients presenting with 
intraocular metastases do not have a known history of cancer.152 Other indications for 
biopsy include discrepancy between non-invasive tests, patient insistence, re-growth 
following treatment  and as part of study protocols.153 
 
Relative contraindications to FNAB include an intraocular tumour for which local 
resection is planned, as further preoperative testing is superfluous. In other 
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situations the risk of complications outweighs potential benefits, as in uveal 
melanoma for which a confident clinical diagnosis is made. Also, sampling small 
melanocytic lesions – which may be naevi or melanomas - may cause further 
diagnostic uncertainty and potential complications.154 
  
FNAB is being performed with increasingly smaller gauge needles and today can be 
performed with a 30-gauge needle. It is feasible to obtain RNA of adequate quality 
and quantity to perform transcriptomic analysis on uveal melanoma samples 
obtained via 25-gauge aspiration biopsy.155 Tumours >10 mm in diameter, >3 mm in 
height and located between the equator and optic disc can easily be sampled trans-
sclerally. Exact placement of the needle is critical. 
 
Complications of FNAB include endophthalmitis, retinal detachment, false negative 
results and tumour dissemination. False negative results are decreased by the 
presence of proficient local cytopathological services.153 Extremely small biopsy 
samples that are insufficient for accurate cytological diagnosis may still be able to 
undergo molecular profiling to give prognostic information.156 
 
4.3  Trans-scleral resection 
Trans-scleral or eyewall resection of uveal melanoma was first described in the 1960s 
by Stallard and Muller.157, 158 The technique has evolved considerably, yet remains 
technically challenging.159 It involves the removal of the intact tumour through a 
large opening in the overlying sclera, if possible without damaging adjacent retina.160  
 
Using a partial thickness lamellar scleral dissection, the tumour is resected from the 
eye with a surround of healthy choroid and the inner scleral lamella, which is in 
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contact with the tumour. The retina is left intact. The operation is performed under 
profound hypotensive anaesthesia.161 Adjunctive brachytherapy with a ruthenium 
plaque is administered, either if clearance is uncertain, or according to the surgeon’s 
preference.145 
 
Trans-scleral resection is a treatment alternative to enucleation in selected patients 
and allows globe retention.161 Contraindications to trans-scleral local resection 
include:145 
 Being unfit for hypotensive anaesthesia 
 Involvement of the optic disc or more than a quarter of the ciliary body, iris or 
angle 
 Diffuse tumour growth 
 Extraocular extension 
 Extensive retinal invasion or perforation 
 
Most large tumours occur in older patients, of whom many have co-morbidities that 
preclude the use of hypotensive anaesthesia. Many patients require additional 
surgery for postoperative complications. These include post-operative vitreous 
haemorrhage, retinal detachment and cataract. Residual tumour is the main 
complication of trans-scleral resection.162 Risk factors for tumour recurrence include 
largest basal diameter >16 mm, advanced age, retinal detachment, posterior tumour 
extension and epithelioid cell type.159, 163Adjuvant radiotherapy of the tumour area 
has been shown to reduce tumour recurrence.162 
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4.4  Endoresection 
Developed independently by Peyman164, 165 and Damato166, primary endoresection is 
highly controversial. It is usually performed with adjunctive ruthenium 
brachytherapy.160 After a standard 3-port vitrectomy, the tumour is removed with a 
vitreous cutter from beneath the retina via a retinotomy.166 Haemostasis is achieved 
by raising intraocular pressure and moderate hypotensive anaesthesia. The retina is 
re-attached using fluid-air exchange and endolaser is used to create a firm adhesion 
around the retinoplexy and to treat any cells that might be left on the scleral surface. 
The air is replaced with silicone oil, which is removed twelve weeks later. 
Cryotherapy is applied to the sclerostomies, and adjunctive ruthenium plaque 
brachytherapy is used in selected cases.  
 
Endoresection has been described as a primary procedure for tumours that are not 
expected to do well after more conventional forms of treatment, or as a salvage 
procedure for patients anticipated to respond poorly to other types of treatment.166 
As a secondary procedure, endoresection can be used after radiotherapy to treat 
exudative maculopathy or to remove apparently active tumour.167 Suitable tumours 
include those extending to within one disc diameter of the optic disc, and growing 
tumours previously treated by radiotherapy.166 The main contraindications are 
involvement of more than a third of the optic disc margin and tumour diameter 
exceeding 10 mm.145 Endoresection does allow for histological and cytogenetic 
processing of the tumour. 
 
Several case series have been reported, and complications include retinal detachment 
and cataract formation.165, 166, 168 A recent review of local treatment failure after globe-
conserving treatment of uveal melanoma found that surgical resection has a higher 
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rate of local treatment failure compared to radiotherapy.169 Endoresection following 
proton beam therapy has been shown to reduce the risk of subsequent neovascular 
glaucoma.170 Some ocular oncologists believe this technique is highly controversial 
and have expressed concern about the possible intraocular dissemination of tumour 
cells at the time of surgery, the lack of prior evaluation in an animal model, and short 
period of follow up.171 It would be difficult to justify endoresection for tumours that 
can satisfactorily be treated by more conventional methods which are explained in 
the following chapter, such as plaque radiotherapy.166  
 






5.1  Radiation 
Professor Konrad Röntgen first discovered electromagnetic radiation in the Bavarian 
city of Würtzburg in 1895. This “new kind of light” was described as “a discovery so 
strange that its importance cannot yet be measured, its utility be even prophesized, or its 
ultimate effects upon long established scientific beliefs be even vaguely foretold… Röntgen 
has given it the name of the X-rays”.172 He was awarded the first Nobel Prize in 1901 “in 
recognition of the extraordinary services he has rendered by the discovery of the remarkable 
rays subsequently named after him”.173 Two years later Henri Becquerel and Pierre and 
Marie Curie were awarded the Nobel Prize for the discovery of spontaneous 
radioactivity.174 Subsequent research uncovered the therapeutic properties of 
radiation.  
 
5.2  Radiotherapy 
Radiotherapy has a long history as a medical therapy. In 1896, less than sixty days 
after the discovery of X-rays, Emil Grubbé treated an advanced ulcerated breast 
cancer with X-rays in Chicago.175 Radiotherapy capitalizes on the energy created by 
the interaction of sub-atomic particles with each other, which can break chemical 
bonds and create ions such as oxygen radicals. Ions are created when an atomic 
particle or photon hits another atom, resulting in loss of a proton, neutron or 
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electron. These ions interact with DNA, causing single- or double-strand breaks, 
base-pair alterations, and interfere with a cell’s ability to repair and duplicate. 
 
Radiation can take the form of electromagnetic waves, particles, or both. 
Electromagnetic (photon) radiation consists of wavelengths from 10-7 m to 10-13 m. 
Linear accelerators produce photon beams with wavelengths in the range of 10-11 m to 
10-13 m. Particle radiation can be electrically charged (protons, electrons) or 
uncharged (neutrons, photons) and interacts with matter by transferring energy as it 
travels through a medium.  
 
Radioactive decay is the process by which the atomic nucleus of an unstable atom 
loses energy in order to return to a stable, low-energy state. Brachytherapy, gamma-
knife radiotherapy, and cobalt-60 machines employ this method. Three types of 
radiation can be emitted by the nucleus during this process: positively charged !-
particles (helium nucleus), negatively charged "-particles (electrons), and # rays with 
no charge. 
 
Teletherapy is the process of delivering ionizing radiotherapy at some distance from 
the patient. A cobalt-60 unit holds a radioactive cobalt source that emits # radiation 
as it decays to nickel-60. The energy of the # photon beam is 1.25 million volts (MV), 
with the maximum dose being delivered to a depth of 0.5 to 1.0 cm.176 A linear 
accelerator is a type of particle accelerator that uses high-frequency electromagnetic 
waves to accelerate charged subatomic particles or ions to high energies through a 
linear vacuum tube. Maximum energies range from 6 to 19 MV, with 80% of the 
maximum dose delivered to a depth of 2 to 6 cm.176 
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Neutron and proton beams have a higher linear energy transfer than photons, 
meaning they release more energy and cause more damage as they pass through 
tissue compared to photons and electrons. A heavy particle accelerator called a 
cyclotron can produce these beams. Proton beams have a characteristic dose 
distribution termed the Bragg peak, with a steep peak of maximal dose and sharp 
subsequent drop-off, which means that most of their energy is deposited at the end 
of its range. The Bragg peak can be manipulated to conform to any tumour size by 
varying the beam energy and is useful for the treatment of tumours located near 
critical structures such as the optic disc or macula.  
 
5.3  Biologic basis of radiation therapy 
Ionizing radiation is characterized by an ability to ionize or expel electrons from 
atoms and molecules. Tissue damage caused by ionizing radiation is due to the 
ejected electrons themselves, which travel at high speeds and randomly go on to 
cause a cascade of further ionizations in the molecules and atoms they collide with. 
Each interaction costs energy and the electron eventually slows to the point where it 
is captured by an atom, molecule or ion, causing the formation of a free radical. 
Usually the electron is captured by water, the most abundant molecule in the cell, 
and reactive oxygen species are formed. These can cause structural alterations in 
DNA, affect cytoplasmic and nuclear signal transduction, modulate the activity of 
proteins and genes that respond to stress and regulate cell proliferation, 
differentiation and apoptosis.177 
 
Ions may also directly interact with DNA, resulting in single-strand breaks, double-
strand breaks, or base-pair alterations, thus impairing a cell's ability to regenerate 
and duplicate. Clusters of ionizations can occur within a few base pairs of DNA, 
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which is present in only two copies and has limited turnover, making it vulnerable to 
permanent damage. As a result, there are complex processes within cells to repair 
DNA. Two main groups of signalling pathways known as sensors and effectors are 
responsible for this process. Proteins actively survey the genome for damage and 
activate three main effector pathways, leading to programmed cell death (apoptosis), 
DNA repair, and temporary or permanent blocks in the cell cycle in response to 
damage.178 
 
Two important proteins in the effector pathway are p53 and MDM2. The function of 
p53 is to regulate genes that control both cell-cycle checkpoints and apoptosis. One of 
the most commonly mutated tumour suppressors, p53 is regulated at the protein 
level by binding to its partner MDM2 and being inactivated. DNA damage 
checkpoints are specific points in the cell cycle at which progression of the cell into 
the next phase can be blocked or slowed. There is a checkpoint at the transition 
between G1 and S phases, the point where the cell decides to initiate cell division 
(figure 5.1). 
 
Double stranded DNA breaks are the most important and difficult lesion to repair. 
There are two ways to repair these lesions. Homologous recombination uses the 
undamaged sister chromatid sequence as a template for repair. This process takes 
hours and can only occur while the cell is dividing in late S- and G2-phases (see 
figure 5.1). Non-homologous end joining is a ‘quick and dirty’ way of repairing 
double stranded DNA breaks.178 Two DNA double stranded breaks are joined 
together without requiring homologous DNA sequences. This is less accurate than 
homologous recombination but occurs in all phases of the cell cycle, is more rapid 
and maximizes a cell’s chance of survival. 
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Figure 5. 1: The cell cycle.179 
 
The radiosensitivity of cells varies 
significantly throughout the cell cycle. 
Cells are most resistant to ionizing 
radiation when they are resting in G0 
phase. After a dose of radiation, cells 
either halt at G1/S or G2/M checkpoint 
and repair is attempted. After a number of 
hours, most cells that are not successfully 
repaired will be halted at G2, unless their cell cycle checkpoints have been damaged. 
A second dose of ionizing radiation will therefore hit more cells in their vulnerable 
G2 phase, causing further damage to DNA. With increasing time after irradiation, 
cells will become more evenly distributed across the cell cycle, a phenomenon 
referred to as redistribution.180 
 
Bergonié and Tribondeau described the concept of radiosensitivity in 1906 and 
offered a prediction about the relative sensitivities of different types of cells to 
radiation.181 They concluded that the radiosensitivity of a cell is directly proportional 
to its reproductive activity and inversely proportional to its degree of differentiation. 
Cells tend to be radiosensitive if they have a high cell division rate, a high metabolic 
rate and an unspecialized phenotype. A single dose of radiation sufficient to control 
a population of rapidly growing cancer cells may result in severe normal tissue 
injury.182 By dividing the total dose of radiation into smaller doses over a period of 
several days, the differential between normal tissue and tumour response to 
radiation is enhanced and toxic effects on healthy cells are minimized.  
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Regaud and Ferroux showed in 1927 that differential radiosensitivity of tissues – in 
this case skin and testis - was increased with dose fractionation.183 A single dose of 
radiation sterilized the testis but caused skin necrosis, whereas sterilization could 
still be achieved with minimal skin reaction if the same dose was given in small 
fractions over a period of weeks. This finding has important implications for 
radiotherapy – by fractionating the dose, growing cancers can be treated with 
relative sparing of normal tissue. A number of factors have been shown to influence 
the outcome of fractionated-dose radiotherapy.  
 
The mechanisms by which fractionation improves targeted killing of tumour cells 
can be explained by the four R’s of radiotherapy: repair of sub-lethal injury in normal 
and neoplastic cells, re-oxygenation of the tumour, redistribution through the cell 
division cycle, and repopulation of surviving normal and malignant cells between 
dose fractions.184 Intrinsic cellular radiosensitivity has been suggested as a fifth ‘R’ to 
account for the different tolerance of tissues to fractionated irradiation.180 
 
Fractionation is beneficial for many normal tissues that proliferate relatively slowly 
and have time to repair damage before replication. Tumour tissue that is rapidly 
proliferating is less able to repair lethal damage to DNA before replication. 
Fractionation also increases damage to the tumour by allowing re-oxygenation of 
hypoxic cells, making them more sensitive to the subsequent dose of radiotherapy.185 
Cells are most resistant to radiation damage when they are in the S phase of the cell 
cycle. After a large dose of radiation, most of the surviving cells will be in the S phase 
and a second dose will be effective only once cells have been given time to redistribute 
throughout the cell cycle before the second dose is given.  
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Melanomas are known to be radioresistant186 and melanoma cells have a greater 
ability than most tumour cells to repair potentially lethal cellular damage between 
fractions of radiotherapy.187 They also have a large proportion of poorly oxygenated 
cells which are generally less sensitive to irradiation than well-oxygenated cells.185 
This means that high doses of radiation must be given to kill tumour cells. 
 
5.4  Plaque brachytherapy for uveal melanoma 
Radiotherapy is the most common organ-sparing treatment for choroidal and ciliary 
body melanoma. The two main types of radiation therapy used in the treatment of 
uveal melanoma are brachytherapy and external beam radiotherapy. Brachytherapy 
utilizes sealed radioactive sources that are placed in direct contact with the tissue to 
be treated. External beam radiotherapy is a type of radiotherapy where the radiation 
source is outside the body. 
 
Brachytherapy was first used to treat uveal melanoma in the 1920s by means of 
radon seeds that were inserted directly onto the intraocular melanoma.188, 189 Radium 
applicators replaced radon seeds as they provided a more homogenous field of 
radiation. Stallard was the first ophthalmologist to successfully treat patients with 
cobalt-60 plaques, publishing a series of 100 patients treated from 1939 to 1964.190 
Plaques used historically include radon gas encapsulated in gold seeds,191 beta-ray 
applicators, and cobalt plaques. Cobalt-60 plaques are infrequently used today, and 
other isotopes that have been used are strontium-90, iridium-192, and palladium-103 
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The inverse-square law demonstrates that the fall-off in dose with brachytherapy is 
inversely proportional to the square of distance from the radiation source. Thus, a 
high radiation dose at the tumour apex requires a much higher dose at the tumour 
base. This is why there is a limit to the thickness of tumours able to be safely treated 
with plaque brachytherapy. 
 
 
In 1949 Freundlich described ruthenium-106 (Ru106) as a candidate for high-dose local 
irradiation.192 The radioisotope Ru106 decays via rhodium-106 to produce the stable 
element paladium-106, producing beta radiation. Tumours best suited for Ru106 
therapy are usually less than 6 mm in height above the scleral surface, lie at least two 
disc diameters from the optic nerve head, and do not involve the ciliary body or 
extend outside the eye.193 However, some centres treat thicker tumours and also treat 
peripapillary melanoma with notched plaques. 
 
Cobalt-60 is a high-energy plaque and can be used to treat thick tumours but also is 
associated with an increased incidence of radiation-induced side effects. Iodine-125 is 
Table 5.1 – Isotopes used in plaque brachytherapy of the eye 1 
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used commonly and was studied in the COMS trial in the treatment of medium-sized 
tumours 2.5-10 mm in apical height.45 Plaques can be fashioned to fit the size of the 
tumour and are sutured to the sclera after careful localization with transillumination. 
The plaque is removed after the appropriate dose of 10,000 rad (100 Gray) had been 
delivered to the apex with seven to fourteen days exposure time. 
 
Local tumour control is an important goal of plaque brachytherapy and tumour 
recurrence is significantly associated with decreased survival.194, 195 Most posterior 
melanomas do not disappear completely after radiation treatment, but show 
significant reduction in size. Risk factors for relapse include older age, greater 
tumour thickness and diameter,196 and proximity of the tumour to the foveal 
avascular zone195 and optic disc.194  
 
5.5  Collaborative Ocular Melanoma Study (COMS) 
In the 1970s, Zimmerman suggested that enucleation of eyes with uveal melanoma 
accelerated metastatic death by disseminating tumour cells into the general 
circulation.141 At the same time, Manschot declared that radiotherapy of uveal 
melanoma was unjustifiable. He histologically showed viable tumour cells after 
radiotherapy and vociferously advocated early enucleation.197 Studies addressing 
survival between enucleation and radiotherapy showed no significant differences but 
were nonrandomized with inadequate patient numbers and short follow-up.198 
 
The Collaborative Ocular Melanoma Study (COMS) was started in 1985 as a 
multicenter randomized clinical trial comparing radiotherapy to enucleation, and 
hoped to resolve the dilemma concerning treatment selection for uveal melanoma. 
Funded by the National Eye Institute, it is the only source of level II evidence for the 
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management of primary ocular melanoma.199 COMS was a three-arm study that 
included two multicentre randomised clinical trials designed to compare (a) the 
effectiveness of brachytherapy to enucleation for the treatment of medium-sized 
choroidal melanomas, and (b) the effectiveness of enucleation with and without 
preoperative external-beam radiotherapy for large choroidal melanomas. The third 
arm was an observational study of small choroidal melanomas. Patient recruitment 
ran from 1987 to 1998. 
 
In the COMS large choroidal melanoma trial, 1,003 patients were studied with 
choroidal melanomas over 16 mm in basal diameter and/or over 10 mm in apical 
height. Subjects were randomised into treatment with enucleation alone or 
enucleation preceded by external beam radiotherapy with a dose of 20 Gy (Gray). 
Five-year survival rates were 57% for enucleation alone, and 62% for enucleation 
plus radiotherapy. Adjunctive radiotherapy did not improve overall survival, 
confirming previous studies, and suggesting that clinically undetectable metastases 
at the time of diagnosis were responsible for many of the deaths of patients with 
large choroidal melanoma.200-202 COMS failed to find any survival difference between 
rival treatments due to insufficient statistical power. 
 
Brachytherapy was selected for the radiotherapy arm of the COMS medium 
choroidal melanoma trial because of the small number of facilities equipped to 
deliver charged particles.203 They recruited 1,317 patients with choroidal melanomas 
ranging from 6 to 16 mm in basal diameter and/or 2.5 to 10 mm in apical height. 
Standardized enucleation was compared to iodine-125 brachytherapy, delivering 85 
Gy to the tumour apex. All-cause mortality at five years was 18% in the enucleation 
group and 19% with brachytherapy. Histologically confirmed metastases at five 
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years occurred in 9% of patients treated with brachytherapy as opposed to 11% of 
patients who underwent enucleation. In the brachytherapy group, there was a 10.3% 
local tumour recurrence rate at five years. Enucleation after brachytherapy at five 
years occurred in 12.5% of individuals. Local tumour recurrence was weakly 
associated with a reduced survival (adjusted risk ratio of 1.5). Decline in visual acuity 
to 20/200 occurred in 43% at three years. Six lines of visual loss occurred in 49% at 
three years. Only two in 660 (0.3%) enucleated eyes were misdiagnosed as having a 
choroidal melanoma. 
 
The COMS small choroidal melanoma trial was an observational study of 204 
patients with tumours measuring 4 to 8 mm basal diameter and/or 1.0 to 2.4 mm in 
apical height. Melanoma-specific mortality was 1% at five years. Clinical growth 
factors included greater initial thickness and basal diameter, presence of orange 
pigmentation, absence of drusen and/or retinal pigment epithelial changes, presence 
of tumour pinpoint hyperfluorescence on angiography. 
 
5.6  Proton therapy 
Proton therapy is a type of external-beam radiotherapy that was first suggested as a 
cancer treatment in 1946204 and began in 1976 as a treatment for uveal melanoma.205, 206 
Protons are positive, charged particles, about 2,000 times the mass of an electron. 
They travel through matter in straight lines, unlike electrons of the same penetrating 
power, which are scattered. In contrast to electrons, protons of the same energy will 
stop at the same depth. The density of ionization along the proton pathway increases 
with distance, due to increased energy loss from interactions with electrons. This 
results in a pronounced increase in dose at the end of the pathway of a proton, 
known as the Bragg peak of ionization. Almost no dose is deposited in the normal 
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tissue beyond the Bragg peak. The energy of a beam of protons can be modulated 
using a combination of protons of different energies, or by scattering the beam to 
broaden the size and depth of the Bragg peak. This allows for localized delivery of 
ionizing radiation. The use of charged particles permits delivery of equivalent 
tumour doses much higher than can be delivered with standard photon therapy, and 
thus higher local control and survival rates are possible.207  
 
A more homogenous dose of radiation energy is delivered to the tumour with proton 
therapy than with a radioactive plaque, which delivers more energy to the base of 
the lesion. Proton therapy is an alternative treatment for tumours that cannot be 
satisfactorily treated with episcleral plaque brachytherapy due to tumour thickness 
or proximity to the optic nerve and other vital structures.208 Because of the ability to 
deliver a high dose to a sharply confined target volume, there is a high local control 
rate (about 96%), a high rate of retention of the eye (85 to 94%) and preservation of 
visual acuity of 20/200 or better in 35 to 75% of patients, depending on the size and 
location of the tumour.207 Complications may arise due to radiation of the anterior 
segment, and manifest most severely as neovascular glaucoma, which occurs in 10% 
of treated eyes. Vision loss occurs in approximately 50%. The main disadvantage of 
proton and ion therapy is the significant cost of the equipment, maintenance and 
staffing needed for such a facility. 
 
5.7  Helium ion therapy 
Helium ion therapy, like proton therapy is widely used for the treatment of medium-
sized tumours. Helium ions contain higher linear energy transfer than protons, 
meaning that they transfer more energy to the matter they pass through. They 
therefore have a greater chance of causing injury to normal tissue anterior to the 
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tumour. In the treatment of a posterior choroidal melanoma, the sharply defined 
helium ion beam passes through the anterior portion of the eye. This results in higher 
irradiation of anterior structures and less radiation to uninvolved regions of the 
posterior pole compared with a brachytherapy source sutured to the sclera. 
Presumably because of this difference in radiation distribution, anterior segment 
complications are seen more frequently with particle beam treatment, while posterior 
complications are more common with radioactive plaques.209 
  
5.8  Stereotactic radiosurgery and radiotherapy 
Stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) are techniques 
that rely on the anatomical confinement of the high-dose volume. They are 
techniques which tightly focus a damaging dose of radiation on a target while giving 
surrounding tissues a low and safe dose. SRS is a total dose given in a single 
treatment event (fraction) and can be given by either a Gamma-knife (using multiple 
cobalt-60 sources) or a linear accelerator. Gamma knife SRS accuracy is enhanced by 
surgical placement of tantalum markers prior to radiotherapy. SRT involves several 
or multiple fractions given by linear accelerator and markers are not used. Precisely 
directed external-beam radiation is delivered from a number of angles to converge 
on the tumour and limit the total dose of radiation to normal tissue. Fractionation 
allows normal tissue to recover between doses, thereby minimising the margin of 
normal tissue included in the radiation treatment volume, and reducing radiation-
related complications.  
 
Fractionated SRT (SRT) is delivered using an eye fixation and monitoring system. 
Patient immobilization is critical to allow precise tumour treatment and limit intra-
fractional patient motion that would otherwise necessitate the use of larger safety 
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margins or repeated verification for each treatment field.210 In a study of 
immobilization devices, the modified Gill Thomas Cosman frame (GTC) provided 
the best control of intra-fractional patient motion and had a 1 mm limit of relocation. 
There was a 95% probability of observing a three-dimensional vector length of 
motion of less than 1.8 mm.210 The GTC frame also allows for relatively fast and 
reproducible setup of the patient at the start of a treatment fraction.   
 
A light source for fixation is attached in front of the healthy or diseased eye, which is 
continuously monitored on a small camera integrated into the mask system. Eye 
movements are viewed on a TV screen in the control room by the radiation 
oncologist who marks the position of the pupil and iris. Treatment is immediately 
stopped if the eye deviates from the primary position.  
 
Treatment planning is based on CT images acquired with the patient in the fixation 
device and their eye in the primary position. Planning for small tumours that are not 
visible on CT scanning is based on clinical photographs. The visible tumour 
extension on CT is known as the gross target volume of the tumour. The clinical 
target volume extends a margin around this to cover microscopic tumour extension. 
Planning target volume is the volume ultimately treated: clinical target volume plus 
a safety margin of 2 mm in all directions, accounting for set-up variations and organ 
motion. The total dose of radiation for a tumour depends on tumour responsiveness, 
the extent of microscopic disease, treatment aims (cure or palliation) and the 
limitations of surrounding tissues. Uveal melanoma is considered to be relatively 
radioresistant, and critical structures surrounding the tumour (lens, optic nerve, 
lacrimal gland, opposite orbit) are vulnerable to damage from radiation. Typical 
doses for uveal melanoma delivered with a 2100 c linear accelerator are 40 to 60 Gy 
 
   60 
with the 80% isodose encompassing the planning target volume and consist of five to 
seven arcs of radiation. All treatments are given in fractions over five to ten days. 
 
5.9  Side effects of radiotherapy 
Ionizing radiation damages cellular DNA and other vital cellular structures leading 
to either immediate cell death or mutations that can take years to cause cell death. A 
number of factors increase the radioresistance of tumour cells, including hypoxia, 
acidosis and free-radical scavengers. A long-term effect of radiation injury is vascular 
damage, primarily due to pericyte death, which usually takes years to develop. 
With plaque radiotherapy, ionizing radiation travels from the plaque through the 
underlying sclera to the choroidal tumour, then on through the retina and vitreous to 
the other side of the eye to exit the globe. Radioactive plaques deliver their radiation 
dose to the structures immediately beneath and around them which may explain 
why there is a higher rate of radiation retinopathy than with other forms of 
treatment.211 
 
External beam charged-particle radiotherapy (helium and proton therapy) is 
delivered via a cyclotron and radiation is directed to the tumour usually from an 
anterior approach. Ionizing radiation passes through eyelids, cornea, sclera, iris, lens, 
vitreous and retina to reach the tumour. Subsequently, these structures may develop 
radiation-related damage, and reports describe a predominance of anterior segment 
complications.212 
 
The vascular effects of radiotherapy are due to intimal thickening and consequent 
reduction in vessel diameter.6 Poiseuille’s equation states that flow is directly 
proportional to the 4th power of the radius; thus reduction in vessel diameter causes 
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vascular insufficiency. Radiation retinopathy results in ischaemia – capillary dropout 
– and exudation – retinal haemorrhages, lipids and oedema. Histopathological 
studies show an obliterative endarteritis characterised by endothelial cell loss and 
thickened vessel walls, leading to microaneurysms, arteriovenous shunt vessels and 
subsequent neovascularization.6 The risk of radiation retinopathy is related to 
effective dose, the presence of systemic disease (such as diabetes mellitus) and the 
use of radiation sensitisers such as chemotherapy. Laser photocoagulation can be 
used to control radiation retinopathy but radiation maculopathy usually results in 
blindness.  
 
Radiation maculopathy develops in approximately 50% of eyes, with poor visual 
outcome. Late complications include macular destruction because of scarring around 
the tumor, optic nerve atrophy, macular degeneration, post-radiation retinopathy, 
cataract, vitreous hemorrhage, secondary glaucoma, thrombosis of the central retinal 
vein, scleral necrosis.213 There have been many articles published on the role of 
bevacizumab in the treatment of radiation maculopathy.  
 
A recent review found that treatment of radiation maculopathy with anti-VEGF 
agents or steroids are effective at reducing macular thickness and improving visual 
acuity.214 They found that there was significant variation in the effect of bevacizumab 
between patients, and a variable requirement of anti-VEGF therapy between studies, 
which may not be completely explained by variations in treatment regimes and 
follow-up. Other treatments that have been used include photodynamic therapy, 
laser and hyperbaric oxygen.214  
 
Exposure to all types of therapeutic ionizing radiations can result in cataract 
formation. The lens is the most radiosensitive ocular structure. It shows clinically 
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visible damage with 0.5 Gy within two to three years215 and there is no threshold for 
cataract development.216 Classically, radiation cataract is described as a posterior 
subcapsular opacification, sometimes with a "doughnut" configuration in the early 
stages.212 Damage to lens epithelial cell DNA is responsible for most radiation 
cataracts. Genomic damage deranges lens fiber differentiation and abnormal lens 
epithelial cells migrate to form a posterior subcapsular opacity. Radiation appears to 
increase the burden of aberrant cells and to hasten cataract onset.  
 
The sclera is the ocular structure most tolerant of ionizing radiation. Scleral necrosis 
usually develops within five years and has an incidence of 1% (73 of 5,057) of 
patients treated with plaque brachytherapy, although it may remain undetected in 
eyes with posterior tumours.215 Plaque radiotherapy requires a dose of 80 to 100 Gy 
of iodine-125 to the tumour apex, resulting in a dose of 350 to 400 Gy to the sclera 
and tumour base. Risks for scleral necrosis include ciliary body and anterior tumour 
location, tumour thickness >6 mm, and radiation dose >400 Gy to the outer sclera.215 
 
Other complications of radiotherapy include neovascular glaucoma, optic 
neuropathy, chemosis, choroidal detachment, and exudative retinal detachment.213 
Factors related to poor visual outcome, including greater tumor thickness, closer 
proximity to optic disc and foveola, submacular fluid, worse pretreatment vision, 
and increasing radiation dose to optic disc, foveola, and lens.217 
 
5.10  Transpupillary thermal therapy 
Infrared laser thermal therapy, referred to as transpupillary thermal therapy (TTT), 
was initially described as an adjunct to plaque radiotherapy by Oosterhuis in 1995.218 
TTT has been used in combination with plaque therapy219 is also known as sandwich 
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therapy.220 Some investigators have subsequently used TTT as a primary treatment 
for small (less than 4 mm in height) choroidal melanomas.221  
 
Using a modified 810 nm wavelength diode laser and a contact lens, 2 to 3 mm 
confluent burns are delivered for one to two minutes over the tumour and around a 1 
mm margin through a dilated pupil via a slit lamp biomicroscope. Up to three 
applications are delivered, three to four months apart.221 The laser spots result in 
temperatures of 45 to 60 °C, causing immediate cell damage and tumour necrosis.222 
Thermal penetration of the tumour reaches a maximum of 4 mm in depth.223 An 
atrophic chorioretinal scar forms over the following months at the site of the tumour. 
 
Advantages of TTT include low cost, immediate tumour necrosis and regression, 
avoidance of radiation retinopathy, as well the ability to treat patients on an 
outpatient basis with local anaesthetic.222, 224 TTT has been used for tumours within 5 
mm of the fovea or optic disc, where radiation would result in potential loss of 
vision. Contraindications to TTT include:145 
 Reduced visibility of the fundus due to media opacities, such as cataract 
 Peripheral tumour location, precluding access to laser 
 Reduced tumour pigmentation 
 
Ideal candidates are monocular patients with a tumour near critical visual structures, 
patients who are unfit for surgery, and patients with advanced diabetic 
retinopathy.223 Complications include epiretinal membrane formation, retinal 
traction, detachment, vascular occlusion and absolute wedge-shaped scotoma.221 In a 
retrospective case series of 135 patients, 32% developed one or more complications, 
often with visual consequences.223 Interest in TTT as primary therapy for choroidal 
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melanoma was based largely on the assumption that it provided better visual 
outcomes than plaque radiotherapy. However, no significant difference was found in 
a retrospective case-matched comparative study that compared TTT or plaque with 
TTT or TTT and plaque radiotherapy.225 
 
Although studies initially were encouraging, concern mounted about the use of TTT 
as a primary treatment due to the emergence of reported high rates of recurrence and 
complications. Local recurrence rates are higher with longer follow-up, and vary 
from 8 to 56%.221 In a non-comparative interventional case series of 256 patients, 
Shields et al calculated a mean of twenty-two months to local recurrence.224 Pooled 
data of ten published case series contained 602 tumours and 100 recurrences, 
excluding eighteen tumours that did not regress with TTT only (primary failures).221 
A weighted mean tumour recurrence rate of 17% was calculated with a median 
follow-up of thirty-seven months.221  
 
Melanoma cells may survive after intrascleral or episcleral TTT because the 
temperature increase in the sclera is lower than that in the tumour. This is because 
less heat from infrared radiation is absorbed in the non-pigmented sclera than in the 
pigmented tumour.220 Risk factors for local treatment failure are increased tumour 
bulk, juxtapapillary location and reduced tumour pigmentation.145 Given that tumour 
recurrence may be associated with metastasis, TTT as primary or sole therapy for 
small choroidal melanomas is not recommended.221 Although it is a minimally-
invasive laser procedure, TTT as a primary therapy carries significant risk of 
morbidity and metastatic disease.223 It has however, been used widely as an adjunct 
to brachytherapy to improve local tumour control and has been used as a treatment 
for macular oedema. 
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CHAPTER 6 




6.1  Study design 
A retrospective review of all patients receiving stereotactic radiotherapy for uveal 
melanoma at Dunedin Hospital between July 2001 and December 2007 was 
completed. Cases were identified through the Oncology Department radiotherapy 
log. All cases with a diagnosis of choroidal or ciliary body melanoma were eligible 
for inclusion in the study. Clinical records of twenty patients were reviewed. These 
included patients referred from other tertiary centres who were not eligible for 
plaque brachytherapy, patients with large tumours who did not want an enucleation, 
and all consecutive patients living in the Otago Region. Cases were identified 
through the Oncology Department radiotherapy log. All cases with a diagnosis of 
choroidal or ciliary body melanoma were eligible for inclusion in the study.  
 
Outcome measurements were (1) local tumour control, (2) visual acuity and (3) 
radiogenic side effects after fractionated linear accelerator-based stereotactic 
radiotherapy. Patient age, tumour size, location, and baseline visual acuity were 
recorded, as well as the presence of symptoms, history of previous cancer or 
diabetes, and past ocular history. Treatment dose and post-treatment visual acuity 
and any adverse effects noted at follow-up were also recorded. Information was 
sourced from clinical patient notes, radiotherapy log, and after writing to the 
primary ophthalmologist for patients who lived in other parts of New Zealand. 
These variables were noted on a data collection sheet (see Appendix), which was 
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then entered into an Excel spreadsheet. Data on ethnicity were retrieved from 
Dunedin Hospital records. In New Zealand, ethnicity is a measure of self-perceived 
cultural affiliation.226  
 
6.2  Ethics approval 
Formal ethics committee approval for data retrieval was gained from the Lower 
South Regional Ethics Committee (LRS/08/03/EXP – see Appendix 2).  
 
6.3  Pre-treatment investigation and treatment planning 
Patients who lived out of Dunedin arrived a week before their treatment and stayed 
a fortnight in total. All patients underwent a detailed history and examination from 
an ophthalmologist. Staging procedures to exclude metastatic disease were 
performed in all patients prior to treatment, including B-scan ultrasound, fundus 
photos, blood tests (complete blood count, liver enzymes), chest x-ray, and liver 
ultrasound scan. A radiation oncologist reviewed patients, and a pre-treatment CT 
scan of the head was performed to enable treatment planning.  
 
The first step in treatment planning involved making a head-fixation device for the 
patient. A modified Gill Thomas Cosman frame (Radionics) was customized with the 
patient’s bite impression and occipital impression to completely immobilize the head 
(figure 6.1). Eye movement was continuously monitored during treatment planning 
and delivery. An eye monitoring system was created using a small charge-coupled 
device camera and fibre optic light source for fixation, which was integrated into the 
mask system in front of the eye being treated (figure 6.2). If the treated eye could not 
fix on the camera due to poor visual acuity, the camera was set in front of the other 
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eye. Eye movements were monitored on a television screen positioned in the control 
room by a radiation oncologist during CT imaging as well as during treatment 
delivery. Control points on the eyelids, the medial and lateral canthi, as well as the 
reflection from the fixation light were marked on the screen. The radiation therapist 




During CT image acquisition for treatment planning the patient was instructed to 
look at the fixation light. Fine-slice CT was performed, with 1 mm slices at 1.5 mm 
increments through the lesion itself, and above and below 1 mm at 3 mm increments 
(Figure 6.3). The goal of treatment planning was to cover the planning target volume 
with the 80% isodose while minimizing radiation exposure to vulnerable structures 
(lacrimal gland, optic disc, lens, skin surface). Contouring was based on a 
combination of CT images, fundal photographs and ultrasound scanning of the 
tumour (Figure 6.4). B-scan ultrasound (10 mHz) provided definition to within 0.5 
mm.  
Figure 6. 1: Gill Thomas Cosman Frame showing bite and occipital impressions 
(images courtesy Dr Lyndell Kelly) 
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Figure 6. 2: Eye monitoring system with closed-circuit television screen and fibre 
optic fixation light (courtesy Dr Lyndell Kelly)  
 
All patients were treated stereotactically with a linear accelerator with 6 MV photon 
beams in ten fractions over five days. Radiotherapy was delivered to patients lying 
supine. Total dose ranged from 45 to 70 Gy.  
 
 
Figure 6. 3 (left): Planning CT scan demonstrating right choroidal melanoma with 
gross target volume and planning target volume and brainstem outlined. Note the 
fixation device and camera in front of the right eye. Figure 6.4 (right): Treatment 
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Oral dexamethasone was commenced in patients treated from May 2006 in an effort 
to minimize post-radiotherapy orbital inflammation. Patients were given 4 mg twice 
daily for ten days followed by a two-week tapering dose. One dose of intravitreal 
bevacizumab (1.25 mg in 0.05 mL) was also given to patients in the week before 
radiotherapy from 2006. This was to ameliorate the effect of VEGF release from 
irradiated melanoma cells. Patients were examined regularly post-treatment, at 
intervals dependent on symptoms and at the discretion of their treating 
ophthalmologist. Those living outside the Otago area were referred back to their 
primary ophthalmologist for follow-up.  
 
6.4  Data management and analysis 
TNM tumour size (see Figure 2.1)51 was determined based on tumour thickness and 
largest basal diameter as measured on B-scan ultrasound. COMS tumour size (see 
Table 2.1)49 was also established from B-scan measurements. TNM tumour staging 
was based on the Seventh TNM Edition (see Table 2.2).51 Tumour volume (cm3) was 
calculated by the radiation oncologist from CT and ultrasound images and was 
summarized using mean and standard deviation. 
 
For this study, best-corrected visual acuity was converted to logarithm of the 
minimal angle of resolution (logMAR) units before analysis. Visual acuities of 
counting fingers, hand movements, light perception and no perception of light were 
assigned values of 1.85, 2.3, 2.6, and 2.9 respectively.227, 228 Visual acuity was then 
converted back to Snellen acuity (table 6.1). 
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Table 6. 1: Visual acuity conversion 
VISUAL ACUITY CONVERSION 
Snellen visual acuity logMAR Snellen visual acuity logMAR 
6/3 -0.3 6/24 0.6 
6/4 -0.2 6/30 0.7 
6/5 -0.1 6/38 0.8 
6/6 0 6/48 0.9 
6/7.5 0.1 6/60 1.0 
6/9.5 0.2 Hand movements 1.85 
6/12 0.3 Counting fingers 2.3 
6/15 0.4 Light perception 2.6 
6/19 0.5 No light perception 2.9 
 
6.5  Outcome measures 
The primary outcome was local control, defined as continuous tumour regression or 
stable disease. Secondary outcomes included visual acuity, adverse effects, and 
metastatic death.  
 






7.1  Baseline characteristics 
A total of twenty-seven patients (16 male, 11 female) were treated from July 2001 to 
December 2007. Mean age was sixty-one years (standard deviation 14, range 27 to 81 
years) and 16 right and 11 left eyes were treated. Seventeen patients were 
symptomatic while ten were discovered incidentally. Three patients had a history of 
diabetes mellitus, two of which had their melanomas diagnosed at retinopathy 
screening.  
 
Table 7.1 presents a summary of demographic and treatment details. Nineteen 
patients were referred from Otago and Southland District Health Boards and eight 
were from other districts. All patients identified their ethnicity as New Zealand 
European. Five patients had a visual acuity of 6/36 or worse in their fellow eye. 
Clinical evidence of metastatic disease was not found in any patients screened at 
presentation. Follow-up ranged from 3 to 104 months (median 14 months). Patients 
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1 F 70 LOCAL S T1a  45 - - 6/6 6/9 44 STABLE  
2 M 50 OTHER M T3b  50 - - 6/6 6/36 19 DEAD UM 
3 M 58 LOCAL M T1a  50 Y Y 6/6 6/7.5 14  STABLE 
4 M 69 OTHER M T2a  50 Y Y 6/18 6/18 3  STABLE 
5 M 40 OTHER M T3a  50 - - 6/24 HM* 8  STABLE 
6 F 53 LOCAL S T1a  50 Y Y 6/6 6/6 12  STABLE 
7 M 72 LOCAL S T1a  50 Y Y 6/7.5 6/9 10   STABLE 
8 M 44 OTHER L T4b  50 - Y 6/24 NPL 14   STABLE 
9 M 58 OTHER L T3a  50 Y Y 6/36 NPL* 12   STABLE 
10 M 62 OTHER L T3b  50 - Y 6/7.5 6/12 3 DEAD UM 
11 M 73 OTHER M T1b  50 - Y 6/7.5 6/9 8   STABLE 
12 F 81 LOCAL S T1a  50 Y Y 6/6 6/7.5 8   STABLE 
13 M 74 OTHER M T2a  50 - - 6/7.5 HM 14   STABLE 
14 M 33 LOCAL S T1a  50 Y Y 6/7.5 6/3.8 10   STABLE 
15 M 66 LOCAL S T1a  50 - - 6/6 6/24 33   STABLE 
16 F 48 LOCAL S T1a  50 - - 6/12 HM 34   STABLE 
17 F 75 LOCAL S T1a  50 - - 6/9 HM 59 DEAD 
18 M 79 LOCAL L T3a  70 - - 6/18 LP* 5 DEAD UM 
19 F 27 LOCAL M T2a  50 - - 6/24 6/60 39  STABLE 
20 M 70 LOCAL L T3a  50 Y Y HM LP 7 DEAD 
21 F 73 LOCAL S T1a  50 - Y 6/4.8 6/7.5 19 DEAD 
22 M 71 LOCAL M T3a  50 - - 6/6 NPL 52 DEAD 
23 M 67 LOCAL S T1a  50 - - 6/9 HM 104 DEAD 
24 F 41 LOCAL M T1a  60 - - 6/30 LP 56 STABLE  
25 F 51 LOCAL S T1a  50 - - 6/6 6/4.8 53 STABLE 
26 F 64 LOCAL L T3a  50 Y Y HM HM 45 DEAD 
27 F 80 LOCAL S T1a  50 - Y 6/9 6/9 52 DEAD 
 
Key: F = female, M = male, DHB = District Health Board, COMS = Collaborative 
Ocular Melanoma Study tumour size, S = small, M = medium, L = large (see Table 
2.1), TNM = Tumour, Node, Metastasis staging (see Table 2.2), Gy = Gray, VA = 
visual acuity, Y = received treatment, HM = hand movements, NPL = no 
perception of light, LP = light perception, *final visual acuity before enucleation, 
DEAD UM = death due to metastatic uveal melanoma 
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Eight patients had a history of previous cancer. Case 12 (see Table 7.1) had previous 
Dukes B bowel cancer resected ten years before presentation. Case 13 underwent an 
orchidectomy for cancer, four years before presentation. Case 15 had a history of two 
cutaneous melanomas excised two years earlier, one on the hand and one on their 
head. Case 18 had a previous pituitary adenoma treated nineteen years before 
presentation with radiotherapy. Case 22 previously underwent radical radiotherapy 
for prostate cancer. Case 27 had a melanoma removed from her face as well as 
treated vulval carcinoma. Case 26 gave a history of low-grade T cell leukaemia, 
treated three years earlier and clinically in remission. Case 10 had a history of 
bilateral choroidal melanoma, which is reported in detail in Section 7.6.  
 
Mean tumour volume was 0.61 cm3 (standard deviation +0.69). Tumours were 
located throughout the posterior uveal tract, at the posterior pole (9), equator (7), 
juxtapapillary (4), ciliary body (4), and macula (3). Using COMS sizing, there were 
twelve small, nine medium and six large tumours. TNM staging was also determined 
using tumour size data, and is displayed in the table above. Nine patients were given 
one dose of intravitreal bevacizumab (1.25 mg in 0.05 mL) in the week before SRT. 
Fourteen patients were given dexamethasone 4 mg twice daily from day one of SRT 
to day seven to control orbital oedema. 
 
 
7.2  Local control and eye retention 
Local control, with clinically stable or regressing tumour size, was achieved in all 
patients. Three patients in total underwent secondary enucleation after SRT. One 
patient (case 9) had a recurrent retinal detachment, making clinical examination of 
the tumour difficult, and the only means of monitoring tumour size was by 
ultrasound. Given that this eye had no vision, the decision to enucleate was made. 
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Case 5 had a recurrent vitreous haemorrhage precluding fundal view, and despite 
vitrectomy and endoresection, went on to have an enucleation due to continued 
vitreous cavity haemorrhage. Case 18 had his eye enucleated for intractable pain.  
 
7.3  Visual acuity 
Of the 24 patients who retained their eye at final follow-up, visual acuity 
deteriorated in eighteen (75%).  Mean Snellen visual acuity of all patients at baseline 
was 6/24 (logMAR 0.64, +0.97), dropping to 6/75 in the 24 patients who retained 
their eye at final follow-up (24 patients, logMAR 1.10, +1.14). Median visual acuity 
similarly decreased from 6/6 (logMAR 0) to 6/21 (logMAR 0.55).  
 
Cases 16, 18, and 24 had tumours involving their macula. Case 16 developed 
radiation retinopathy, treated with intravitreal bevacizumab and pan-retinal 
photocoagulation. Case 18 had his T3a tumour treated with a cumulative dose of 70 
Gy. He had his eye enucleated for pain ten months later and died of metastatic 
disease six months after enucleation. Decreased vision in Cases 1 and 11 was due to 
cataract. Case 10 developed peripheral corneal thinning with dry eye. 
 
Seven patients developed maculopathy, which limited their vision. Case 7 had 
atrophic age-related macular degeneration (ARMD) at baseline which continued to 
progress. Case 21 also had ARMD with a choroidal neovascular membrane. Cases 2, 
13, 15, 19, and 23 developed ischaemic maculopathy. Case 2 presented with a T3b 
tumour at his ora, involving the ciliary body. He developed neovascular glaucoma, 
which was controlled on medical treatment, but went on to die of metastatic disease 
despite chemotherapy, sixteen months after SRT. Cases 13, 15 and 19 also developed 
dry eye symptoms. Case 15 and 19 underwent cataract extractions. Case 23 had a 
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juxtapapillary T1a tumour and developed optic neuropathy in addition to ischaemic 
maculopathy.  
 
Nine patients presented with exudative retinal detachments and in four patients 
these became chronically detached. Case 8 presented with a large T4b tumour 
involving the ciliary body in his only eye. He developed a chronic total retinal 
detachment with rubeosis and a normal intraocular pressure. He then underwent an 
endoresection with debulking of the treated tumour, followed by cataract extraction 
and pars plana vitrectomy with silicone oil. Case 9 had an enucleation for chronic 
exudative detachment fifty weeks after SRT. Case 20 had a total exudative 
detachment with “kissing retina” at last follow-up. Case 22 also developed a total 
exudative retinal detachment with cataract. 
 
Two patients developed non-clearing vitreous haemorrhages. Case 5 underwent a 
vitrectomy and trans-scleral local resection but his eye was subsequently enucleated 
due to recurrent haemorrhage. Case 17, seventy-five years old, had type one diabetes 
mellitus with moderate non-proliferative diabetic retinopathy pre-treatment. She 
developed bilateral vitreous haemorrhages despite pan-retinal photocoagulation. 
 
7.4  Radiation-related side effects 
A total of eight patients had documented radiation retinopathy, involving the macula 
in five patients as described above. Two patients developed neovascular glaucoma 
(cases 2 and 8), and case 23 developed optic neuropathy. In general, these patients 
had worse visual outcomes. Four patients had significant dry eye symptoms (cases 
10, 13, 15 and 24). Cataract was documented in five cases (1, 10, 15, 19, 22). 
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7.5  Metastatic death 
Ten patients were known to have died by final follow-up, of which the cause of 
death was known for four patients. Case 23 died of metastatic bowel cancer, and 
three others (cases 2, 10, 18) were known to have died of metastatic uveal melanoma 
at final follow-up.  
 
7.6  Case report 
Case 10 - a fifty-three year-old male - was initially referred in 1998 by his optometrist 
who noted conjunctival pigmentation. This had been present for twenty years. The 
patient had bilateral oculodermal melanocytosis, with slate grey pigment in the 
episclera, both superiorly and inferiorly. A small amount of skin around the left 
lower punctum was also affected. His medical history included myopia, ischaemic 
heart disease and elevated cholesterol.  
 
In 2001 he presented with reduced left visual acuity of 6/12 due to a left non-
ischaemic infero-temporal branch retinal vein occlusion (BRVO) with mild macular 
oedema. Initially, a raised grey mass was noted in the left nasal fundus, measuring 
8.0 mm wide and 3.5 mm thick with ultrasonography. He had no evidence of 
metastatic disease. Given the location of the melanoma and the presence of a left 
BRVO it was felt that trans-pupillary thermotherapy (TTT) would be an appropriate 
treatment. He underwent three courses of TTT over six months and his lesion 
responded to treatment. 
A year later he was diagnosed with a right supero-temporal choroidal melanoma. It 
was contiguous with the ciliary body, measuring 4.6 mm in height on ultrasound 
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scan with a basal diameter of 9.2 mm. Visual acuities were 6/7.5 right and 6/18 left. 
He was treated with iodine-125 brachytherapy.  
 
Two years later, having developed an epiretinal membrane, he underwent a left 
vitrectomy and epiretinal membrane peel, and corrected visual acuity improved 
from 6/30 to 6/15. The following year he underwent bilateral cataract extractions. In 
2007 he was noted to have a raised pigmented lump supero-temporally on the 
external right globe, with some hollowing out on the inside, where the right 
choroidal melanoma (treated with radioactive iodine plaque) had been located. 
Fundus examination, B-scan and MRI scan found no evidence of any residual solid 
tumour. 
 
The patient was followed at six-monthly intervals. In 2008, a year after an MRI scan, 
sentinel vessels were found on the external surface of the right eye and an inferior 
ciliary body melanoma was present with an apical thickness of 10.5 mm on 
ultrasonography. This was non-contiguous with the previous supero-temporal 
lesion. He was referred for fractionated stereotactic radiotherapy and received 50 Gy 
in five fractions over a week. Six arcs were used over a wide field.   
 
The patient then developed severe external eye disease with bilateral involvement of 
the meibomian glands as well as peripheral corneal thinning. A staging CT scan of 
his eye and orbit was performed three months after radiotherapy. This showed a 
suspicious area of soft tissue opacification in the infero-medial quadrant of the right 
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orbit, which possibly represented extra-scleral extension or metastasis of the 
melanoma. Ultrasound scan of his liver revealed a solitary metastasis. The patient 
died four months later at the age of sixty-three, seven years after the diagnosis of his 
first tumour. 
 






8.1  International data 
 
This study was a retrospective audit of the first cohort of patients with ciliary body 
and choroidal melanoma treated in New Zealand with fractionated SRT. Stereotactic 
radiotherapy for the treatment of uveal melanoma is a relatively new procedure. 
Case series of Linac-based SRT have been reported in the literature from Austria,229, 
230 the Netherlands,231 Canada,232, 233 Japan234, Germany,235 China236 and Spain.237 
 
Table 8.1 summarizes the findings from the international literature. The largest series 
published is from the Vienna University group, with up to ten years of follow-up.230 
They treated 212 patients with choroidal melanoma according to a prospective 
protocol if they were unsuitable for brachytherapy with ruthenium-106 or local 
resection. Initial tumour height was at least 7 mm, or more than 2.5 mm in cases of 
juxtapapillary or juxtamacular tumours. The first 24 patients received a total dose of 
70 Gy to the 80% isodose, which was reduced to 60 Gy for the next 158 patients, and 
further reduced to 50 Gy for subsequent patients. They found no significant 
difference in outcomes, although follow-up in the 50 Gy cohort was shorter. They did 
find that the time for visual acuity to drop below 0.1 was faster in the 70 Gy group 
(which had 14 Gy fractions) compared to the lower doses. There were 39 
enucleations (18%) during the follow-up period, and the most frequent causes of 
enucleation were neovascular glaucoma (25 cases) and recurrent tumour growth (8 
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cases). The majority of patients had a decrease in vision. Tumours near the macula 
and close to the optic disc have a worse visual prognosis and higher risk of local 
recurrence, which was reflected in their findings. They concluded that their local 
control rates were similar to proton therapy. 
 
Another prospective longitudinal cohort study has been reported from the 
Netherlands.231 A total of 102 patients with choroidal or ciliary body melanoma were 
prospectively evaluated at a single institution. Tumours were 12 mm thick or less 
with a diameter less than 16 mm. A total dose of 50 Gy was delivered in 10 Gy 
fractions on five consecutive days. Follow-up was relatively short with a median of 
32 months (range 2-92). Fifteen enucleations were performed (15%), mainly for 
neovascular glaucoma (8) and progression (4).   
 
A retrospective review from Montreal233 reported on 50 consecutive patients with 
juxtapapillary choroidal melanoma (tumours within 2 mm of the optic disc). Most 
patients had 60 Gy delivered in 10 fractions over two weeks. A similar series in 
Toronto delivered higher doses of 70 Gy in five fractions.232 This study compared SRT 
with iodine-125 brachytherapy and found that SRT had higher radiation-induced 
comorbidities at four years. There was no mention of visual acuity outcomes but an 
earlier case series from the same institution looked at 28 patients with juxtapapillary 
choroidal melanoma. These were treated with 70 Gy in five fractions over ten days 
and found initial median Snellen acuity at 20/100, which dropped to counting 
fingers vision at 18 months.238 
 
An older case series from Japan presented 16 patients with choroidal melanoma of 
heterogenous size and location.234 The first eight patients received hyperthermic 
treatment to the surface of the cornea in an attempt to heat the melanoma and make 
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it more radiosensitive. A range of SRT doses were given and follow-up was relatively 
short. A group in Germany studied SRT of choroidal tumours – both melanomas and 
choroidal metastases.235 The melanoma group comprised ten patients who were 
treated with either 12-20 Gy in one fraction or 30 Gy in 10 fractions. 
 
A group in Spain evaluated a technique of eye immobilization by eyelid closure 
during SRT.237 They treated five patients with choroidal melanoma in this way and 
recommended safety margins of 3 mm for this technique. A report from China 
described 16 patients with choroidal melanoma who were given a range of doses.236 
Two patients had single doses of 35 Gy and 25 Gy and the remaining patients had 30-
55 Gy in 2-4 fractions over 4-16 days. Seven patients underwent enucleation for 
neovascular glaucoma (3), tumour growth (2) and corneal ulcer (2). At final follow-
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Key: Gy = Gray, HM = hand movements, yr = year 
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8.2  Radiation dose 
Uveal melanoma is known to be radioresistant, and high radiation doses are required 
to treat tumours. Most patients (24/27) in this audit received a total dose of 50 Gy to 
the 80% isodose line surrounding the tumour with a 2 mm margin as planning target 
volume. The first three patients received a total dose of 45 Gy, 70 Gy and 60 Gy 
respectively. It is interesting to note that a number of centres reduced the radiation 
dose in their treatment regimes over time to minimize radiation-related side effects. 
The Vienna group found no significant difference in outcomes for 50-60 Gy groups, 
but those treated with 70 Gy tended to drop visual acuity faster than those treated 
with lower doses.229 
 
Given that high doses are required for local tumour control, it is inevitable that 
surrounding structures get relatively high radiation doses in the area around the 
planning target volume. In this study of twenty-seven patients, radiation retinopathy 
was documented in eight cases, optic neuropathy in one case, and cataract in five 
cases. The two patients who developed neovascular glaucoma had the largest 
tumours of the group – T3b (case 2) and T4b (case 8). The Vienna group found that 
largest tumour diameter was an important prognostic factor for radiogenic side 
effects, and that optic neuropathy and radiation maculopathy were increased by 
virtue of the fact that these tumours were posteriorly located.229  
 
8.3  Eye retention 
Eye retention is one of the main advantages of SRT, however secondary enucleation 
may be performed if local control fails or significant tumour- or radiation-related 
side effects occur. Three of twenty-seven patients (11%) underwent secondary 
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enucleation after median follow-up of fourteen months in this study, for recurrent 
vitreous cavity haemorrhage (case 5, Table 7.1), recurrent retinal detachment (case 9, 
Table 7.1), and intractable pain (case 18, Table 7.1).  Table 8.2 outlines reasons for 
enucleation from international data. The most common cause for enucleation was 
neovascular glaucoma, followed by tumour growth.  
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Montreal 3/50 6 1 1   1    
Tokuuye234 
Tokyo 2/15 13 1 1       
This study 3/27 11    1 1   1 
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Fernandes et al in Toronto documented ten eyes with juxtapapillary choroidal 
melanoma treated with SRT doses of 70 Gy (in 5 fractions over 10 days) were 
enucleated due to neovascular glaucoma (6) and tumour progression (4).239 Retinal 
damage and radiation-induced retinal vascular changes were more prominent in the 
NVG group and there were no features of radiation damage in the anterior 
chambers, leading researchers to conclude that NVG is due to radiation damage in 
the posterior of the eye rather than primary damage to anterior segment structures.239 
 
A retrospective study from the Netherlands analysed 118 consecutive patients 
treated with fractionated SRT for choroidal and ciliary body melanoma.240 Median 
follow-up was 4.7 years, during which time 19 patients (16%) underwent secondary 
enucleation. Six were due to failure of local tumour control (5%), 12 due to 
neovascular glaucoma and one due to diffuse radiation retinopathy. They found that 
the overall risk of secondary enucleation following SRT increased significantly with 
tumour height. 
 
The Collaborative Ocular Melanoma Study reported on secondary enucleation 
following iodine-125 brachytherapy.241 A total of 650 patients received 
brachytherapy, and 85 patients underwent enucleation (13%).  They reported a 12.5% 
rate of secondary enucleation within five years of treatment. Half of patients were 
enucleated due to failed local control and the remainder were due to pain and poor 
vision. Histopathological analysis found that 55% of eyes had vascular abnormalities 
suggestive of radiation retinopathy. 
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8.4  Visual acuity 
The lens, macula and optic nerve are critical parts of the visual pathway that are 
vulnerable to radiation damage. The lens is the most radiosensitive ocular structure, 
and has no threshold radiation dose for cataract formation.216 Cataract extraction is 
usually straightforward and reverses lens-related visual impairment, however 
ischaemic radiation retinopathy and optic neuropathy can be very difficult to treat.  
 
It has been widely noted that visual acuity decreases post-radiotherapy and a 
number of factors account for this. Tumours at the posterior pole are close to the 
macula and optic nerve and by virtue of their location become susceptible to 
collateral radiation-induced ischaemia. In this study, visual acuity decreased in 
three-quarters of patients who retained their eye (18 of 24 patients), with median 
Snellen acuity dropping from 6/6 to 6/21.  
 
8.5  Study strengths 
All patients who were treated with SRT in Dunedin within the 7.5-year period were 
included in this study, and clinical notes could be located for all patients. 
 
8.6  Study limitations 
By virtue of the retrospective nature of this study, information was limited to that 
data recorded in clinical notes. Side-effects not recorded may not have been 
specifically asked about, or may have not been deemed sufficiently significant for the 
doctor to record. Visual acuity was converted from Snellen scores at six metres and 
four metres recorded in different hospitals to the logMAR equivalent. B-scan is also 
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operator-dependent and not all patients had their scans done in the same hospital by 
the same radiologist.  
 
The treatment regime evolved over the course of the audit period. The radiotherapy 
dose changed with the first three patients receiving a total dose of 45, 70, and 60 Gy 
respectively, and the following 24 patients receiving 50 Gy. Dexamethasone was 
introduced to control orbital inflammation, and intravitreal bevacizumab was 
administered prior to radiotherapy from 2006. Due to small numbers, this study has 
insufficient power and it is difficult to measure the effect of these interventions. 
 
8.7  Case study 
We reported the case of a patient with oculodermal melanocytosis with two uveal 
melanomas in one eye and another uveal melanoma in the opposite eye. This is a 
very rare occurrence and illustrates the inadequacy of our current diagnosis and 
treatment of this cancer – metastatic disease often occurs before the primary tumour 
is diagnosed. 
 
8.8  Conclusions 
Uveal melanoma is a rare disease and it is very difficult to conduct an adequately 
powered study in the New Zealand population. This retrospective audit supports 
international literature that fractionated stereotactic radiotherapy is a useful addition 
to the range of eye-sparing treatment for uveal melanoma.  
 
Randomized controlled trials that are underpowered do not adequately test the 
underlying hypothesis and are considered by some as scientifically useless and 
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therefore unethical.242 However, an underpowered trial could be justified if the 
authors explicitly plan to combine their prospective trials with other similar ones 
with comparable research methods for a prospective multicentre meta-analysis.243  
 
8.9  Future directions 
This study has shown that SRT for the treatment of uveal melanoma is an area 
worthy of further research. Since data on this cohort was collected, there have been 
no major changes to the management of patients undergoing SRT for uveal 
melanoma. A national ocular cancer database with patient information could be 
established to accrue larger patient numbers and enable ongoing audit and 
prospective studies. Areas for further research include quality-of-life, cost-benefit 
analyses, dose fractionation, treatment response as a function of tumour gene 
analysis, and the role of adjunctive steroid therapy and intravitreal bevacizumab. 
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Appendix 1: Data collection sheet 
S T E R E O T A C T I C  R A D I O T H E R A P Y  O F  U V E A L  M E L A N O M A  –  D U N E D I N  2 0 0 1 - 2 0 0 7   
D r  G e n e v i e v e  O l i v e r ,  P r o f e s s o r  A n t h o n y  C B  M o l t e n o ,  D r  L y n d e l l  K e l l y  













Type of Cancer Melanoma Metastasis Other 
Eye    Right  Left Both 
At Diagnosis Age Date 
Documented Growth Yes No 
Clinical Features at presentation 
Size Pigmentation Lipofuscin Serous Ret Detachment 
Symptoms – No Symptoms- Yes: 
Ultrasound Features (mm) Height:  Width:                          Thickness: 
Apex Height From: Inner Scleral Surface Outer Scleral Surface 
Lesion Margin at  
Disc Fovea Pre-Equatorial Equatorial 
Ora Ciliary Body   
BCVA / IOP at diagnosis R R              mmHg L L                 mmHg 
Pre-existing optic disc pallor? Yes No 
Pre-existing cataract None / Cortical Nuclear Sclerosis / PSCO Other: 
Other ocular conditions:  
Systemic work-up  CXR Abdo USS 
   








Date Started – Completion   Duration 
Prescribed dose Fractions Size 
Prescription isodose level  Vol. within Rx isodose 
Max dose in GTV  Min dose in GTV 






Follow-up visit / date 1 2 3 4 5 6 
Months post-treatment       
Size Melanoma (DD)       
USS Height / Width / Thickness       
IOP affected eye (mmHg)       
VA affected eye       
Metastasis? Y / N Y / N Y / N Y / N Y / N Y / N 
Death – cause / date  
Ocular comorbidities affecting VA  
XRT Complications New cataract Radiation Retinopathy Neovascular Glaucoma Optic Neuropathy 
Others (specify)  
Further Treatment Plaque Enucleation Other 




Appendix 1 – Patient data sheet. BCVA = best-corrected visual acuity, IOP = 
intraocular pressure, PSCO = posterior subcapsular opacity, CXR = chest x-ray, 
USS = ultrasound scan, GTV = gross target volume, DD = disc diameters, VA = 
visual acuity, XRT = radiotherapy  
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